Reports from the Mountsberg Wildlife Centre

Treatment of Osteoporosis

2008-07-04T03:50:00.001-07:00

Return to: The 1st Joint Meeting of the International Bone and Mineral Society and the European Calcified Tissue Society

Previous Article Next Article

Treatment of Osteoporosis CME

Disclosures

Ego Seeman, MD, PhD

Many advances have taken place in the treatment of osteoporosis. With improvement in the quality of the design and execution of clinical trials undertaken during the past 10-15 years, inferences can be made with greater confidence regarding antifracture efficacy of more recently investigated antiresorptive drugs such as the bisphosphonates, alendronate and risedronate, and the selective estrogen receptor modulator (SERM), raloxifene. These drugs continue to be studied and some new data were presented at the 1st Joint Meeting of the International Bone and Mineral Society and the European Calcified Tissue Society. However, probably the most exciting advance that has taken place in the study of antiosteoporotic drugs concerns the accumulating evidence that the anabolic agent parathyroid hormone (PTH) and certain of its amino acid fragments can rebuild the eroded, aged skeleton. Further refinements of recently published studies as well as further evidence for its mechanism of action and its antifracture efficacy were presented at this conference.

Antiresorptive Drugs

A reduction in risk for spine fracture using alendronate, raloxifene, or risedronate is observed early in the course of treatment, within the first 12-24 months.[1-5] These drugs reduce the risk of single or multiple fractures, and they reduce the risk of symptomatic as well as morphometric (asymptomatic) spine fractures. These effects are documented in women with osteoporosis with a prevalent fracture for alendronate, raloxifene, and risedronate, but only alendronate and raloxifene have been reported to reduce the risk of spine fractures in women without a prevalent fracture. Whether the risk reduction observed with these drugs is sustained beyond 3-4 years is unclear at this time, but some evidence for a sustained effect was reported at this conference. Some evidence was also presented to suggest that risedronate reduces the risk of spine fractures in patients with osteopenia.

Nonspine fracture rates are reduced with alendronate and risedronate, but there is no evidence for this with raloxifene. The antihip fracture efficacy data are difficult to interpret, but the available evidence suggests that alendronate and risedronate are both likely to reduce the risk of hip fracture in ambulant women.[1,2,6] In the alendronate trials, hip fracture was not a primary end point, but there was consistency in the fracture risk reduction across several trials. However, event rates were low, and confidence intervals overlapped unity except in the fracture arm of the Fracture Intervention Trial (FIT) and in the subjects with osteoporosis in the nonfracture arm of FIT. In the risedronate trial, hip fractures were the primary end point, there were many events, and there was a significant reduction in fracture risk in women with osteoporosis aged 70-79 years but not in women over 80 years of age (the source of 50% of all hip fractures). Estrogen, etidronate, calcitonin, and vitamin D metabolites may prevent fracture, but, for historical and other reasons, flaws in design, execution, and analyses (small sample sizes, trial brevity, unplanned pooling of groups, subgroup analyses, selective presentation of data, dropouts, unblinding, lack of controls) make the results difficult to interpret. Several advances in the study of these agents were presented at this conference.

BisphosphonatesThe bisphosphonates are the most thoroughly investigated drugs in the field of osteoporosis. In general, the results of the trials are reported as a single figure, the risk reduction relative to controls, despite the fact that subjects range in age from 50-80 years and are treated for 3-4 years. The reduction in fracture risk is usually seen within the first 12-18 months of treatment. It is unclear whether the reduction in risk applies to all age groups and whether the risk reduction is sustained or lessens with time.

To address whether the global fracture risk reduction using alendronate was age-specific, M.C. Hochberg of the University of Maryland, Baltimore, and colleagues[7] report the relative and absolute risk reduction for the hip, spine, or forearm in 3658 women with osteoporosis from FIT. The age groups studied were: 55-65, 65-70, 70-75, and 75-85 years. The relative risk reduction for hip, spine, and forearm fractures over the trial were 53%, 45%, and 30%, respectively, and did not depend on age. The absolute risk reduction (ARR) was small in the younger age groups because of the low frequency of events and increased with advancing age. For the hip, the ARR (number per 100 patient-years) ranged from 0.13 (55- to 65-year-olds) to 0.53 (75- to 85-year-olds). The corresponding ARRs for spine fractures were 0.14 and 0.86. The number needed to treat (NNT) for 5 years for the hip fracture risk reduction was 157 for 55- to 65-year-olds and 45 for 75- to 85-year-olds. The corresponding NNTs for the spine were 140 and 23.

For a drug to be regarded as having a sustained effect, the risk reduction seen during the first 12-24 months of treatment should also be seen subsequently. Usually, results are presented as the cumulative numbers of women who fracture during 3-4 years of a study. The curves depicting the placebo and treatment diverge during the first 12-24 months, but whether they continue to do so, or become parallel, may be difficult to discern. In a 2-year extension study of the risedronate trial, D. Hosking, Nottingham City Hospital, Nottingham, England, and colleagues[8] report that treatment with risedronate for 5 years reduces fracture risk. Of the patients who completed the 3 years, 135 received risedronate 5 mg and 130 received placebo; 82% completed the study. In years 4-5, risedronate reduced the incidence of new spine fractures (risedronate, 11.1%; placebo, 22.3%; P = .011). These data are encouraging but should be interpreted cautiously, as the sample represents only a small fraction of the original sample randomized to placebo or control group.

Although anti-spine fracture efficacy of the bisphosphonates is well documented in patients with osteoporosis, the antifracture efficacy of bisphosphonates in patients with osteopenia is less clear. S.A. Quandt, Wake Forest University, Winston-Salem, North Carolina, and colleagues[9] report that alendronate reduced the risk of clinical vertebral fractures in women with osteopenia. The investigators studied 3740 women, aged 55-80 years, with bone mineral density (BMD) T-score > -2.5 at the femoral neck — 942 with an existing morphometric vertebral fracture and 2799 without; 1859 were treated with placebo and 1881 were treated with alendronate 5 mg daily for 2 years and 10 mg up to 4.5 years. Alendronate reduced the risk of clinical vertebral fractures by 60% (RR = 0.40 [0.19, 0.76]). The risk reduction was 0.34 (0.12, 0.84) in those with prevalent fractures and 0.46 (0.16, 1.17) in those without prevalent fractures. Although the point estimates do not differ much, the confidence interval for the latter overlaps unity, suggesting that alendronate may reduce fracture risk in women with osteopenia alone, but prospective studies are needed to demonstrate any benefit convincingly.

If a drug reduces the risk of fracture in patients with osteoporosis with prevalent fracture, is it reasonable to infer that the drug will be efficacious in patients without a baseline fracture? This probably cannot be inferred because fracture rates are very much higher in the former, so that the ability to demonstrate a fracture risk reduction of a drug when event rates are low requires very large sample sizes.

The studies of the anti-spine fracture efficacy of risedronate were done in patients with a prevalent fracture. To determine whether this drug reduces the risk of fracture in patients with osteoporosis without a baseline fracture, I. Fogelman, Guy's Hospital, London, England, and colleagues[10] pooled the results of the subgroups of patients with low BMD from 3 risedronate studies and the Hip Intervention Program (HIP) study. The studies ranged from 1.5-3 years in duration and included 383 patients ranging in age from 63-71 years with no prevalent vertebral fracture and a spinal BMD T score less than -2.5 SD. Risedronate reduced the risk of a first vertebral fracture by 70%. These results should be viewed with caution, as they are derived from post-hoc analyses of studies designed to examine the effect of risedronate on BMD, not fractures. Small numbers resulted in wide confidence intervals even though the point estimate for risk reduction favors the drug.

Gastrointestinal Effects of BisphosphonatesThe bisphosphonates may result in upper gastrointestinal (GI) irritation. A great deal of debate continues regarding the relative safety of alendronate and risedronate. P.D. Miller, Colorado Center for Bone Research, Lakewood, Colorado, and colleagues[11] examined the upper GI tolerability of alendronate and placebo in postmenopausal women with osteoporosis who discontinued alendronate because of an upper GI adverse experience. Subsequent rechallenge with alendronate or placebo in a double-blind, randomized, parallel-group, placebo-controlled administration of alendronate 10 mg daily or placebo daily for 8 weeks resulted in a cumulative incidence of patients who discontinued because of upper GI intolerance of 14.5% (alendronate, n = 88) and 17.3% (placebo, n = 84). The data suggest that cautious re-exposure to treatment is a reasonable approach given that tolerance to treatment was achieved in about 85% of the subjects.

In a 2-week study, A.B.R. Thomson, University of Alberta, Edmonton, Alberta, Canada, and colleagues[12] compared gastric ulcer incidence after treatment with risedronate (5 mg, n = 318) or alendronate (10 mg, n = 317) in healthy postmenopausal women stratified by Helicobacter pylori (HP) status. Subjects were randomized to risedronate (5 mg, n = 318) or alendronate (10 mg, n = 317). Evaluator-blind assessment of the esophageal, gastric, and duodenal mucosa was performed at baseline and on days 8 and 15. The overall incidence of gastric ulcers (> 3 mm) was 6.0 vs 12.1% in the risedronate vs alendronate groups, P < .05). In HP-positive subjects, gastric ulcer incidence was 3.9 vs 13.9% (P < .05). In HP-negative subjects, gastric ulcer incidence was 6.7 vs 11.5% (NS). Ulcers greater than or equal to 5 mm were noted in 3.3 vs 7.7%. Mean gastric endoscopy scores at days 8 and 15 were lower in the risedronate group (P < .001). Mean esophageal and duodenal endoscopy scores were similar in the 2 groups at days 8 and 15. Clinical upper GI adverse events occurred in more subjects receiving alendronate (8.8% vs 5.7%, n = 18). The investigators report that HP did not increase the incidence of bisphosphonate-related GI injury.

S. Adami, Clinicizzato di Valeggio, Valeggio, Italy, and colleagues[13] blindly randomized 66 postmenopausal women who discontinued alendronate 10 mg/day as a result of upper GI adverse events to risedronate (5 mg/day, n = 35) or placebo (n = 31) for 3 months. The investigators found that 16.1% of patients in the placebo group and 11.4% in the risedronate group discontinued because of upper GI adverse events. The percentage of patients reporting any upper GI adverse event was similar between the 2 groups (19.4% and 20% for placebo and risedronate, respectively). Although the authors conclude that risedronate is as well tolerated as placebo in patients who could not tolerate alendronate, the inference that this drug is better tolerated than alendronate cannot be made from this study; given that 80% of subjects with GI intolerance during alendronate therapy tolerate the medication on re-exposure, an alendronate arm should have been included as well.

Given the common occurrence of upper GI irritation in the community and the tolerance of bisphosphonates on re-exposure, the interpretation of short-term studies lacking a positive (nonsteroidal anti-inflammatory agents) or negative (placebo) control group is difficult. In a systematic review of available evidence, B. Cryer, University of Texas Southwestern, Dallas, and D. C. Bauer, University of California, San Francisco,[14] report that endoscopy trials that were appropriately blinded and of longer duration (4-10 weeks) found no difference between alendronate and risedronate or placebo, even at the higher doses used for once-weekly dosing or to treat Paget's disease. Randomized, blinded, controlled trials with clinically relevant GI end points, in which large numbers of patients participated for up to 7 years, were regarded as the highest level of evidence. The incidence of upper GI irritation complaints was about 30% in these studies and was comparable to that for placebo. Further, the incidence of worrisome upper GI irritation events was low and comparable to that seen with placebo. Two studies of patients who previously had intolerance to bisphosphonate reported that most (about 85%) were able to continue alendronate or risedronate when treatment was resumed, and the permanent discontinuation rates were no higher than with placebo. The authors infer that any increase above placebo in clinically relevant upper GI problems related to bisphosphonate use is very low.

EstrogenHormone replacement therapy (HRT) has been used for many years in the treatment of osteoporosis. However, for all of its popularity, the efficacy of HRT in preventing spine and nonspine fractures is based more on opinion than on evidence. There are only 2 prospective placebo-controlled trials examining the anti-spine fracture efficacy of estrogen.[15,16] Lufkin and colleagues[15] reported that transdermal estrogen resulted in an increase in BMD during 1 year. Eight fractures occurred in 7 of 34 women (21%) given HRT, while 20 fractures occurred in 12 of 34 women (35%) given placebo. The reduction in fracture events was significant, but the reduction in numbers of patients with fractures was not. In the study by Lindsay and colleagues,[16] vertebral deformities were less common among patients treated with the estrogen, mestranol, than among controls.[16] Among 42 placebo-treated and 58 estrogen-treated women reviewed after 6-12 years, 16 placebo-treated patients (38%) lost a mean of 0.9 cm in height, while 2 (3.4%) lost height in the HRT-treated group.

Reduction in nonvertebral fracture risk with HRT has not been assessed in a well-conducted, prospective, double-blind, randomized, controlled study. The view that HRT reduces nonvertebral fractures, including hip fractures, is based on retrospective and prospective cohort studies, or case-control studies. In all of these studies, the possibility that healthier individuals (who fall less frequently or have higher bone density) received treatment cannot be excluded.

At this conference, D. J. Torgerson and S. E. M. Bell-Syer, University of York, England,[17] examined the effects of HRT on nonvertebral fractures in a meta-analysis of 23 trials involving over 8000 patients. There was a 21% reduction in nonvertebral fractures, (RR = 0.79 [0.68-0.93]). Among women younger than 60 years, there was a significant 36% risk reduction (RR = 0.64 [0.49-0.83]), but for those older than 60 years, the risk reduction was 9% (RR = 0.91 [0.74-1.12, NS]). As most nonvertebral fractures occur in women older than 60 years, these data do not support the use of HRT in this age group.

L. Mosekilde, Aarhus University Hospital, Aarhus, Denmark, and colleagues[18] report the results of a prospective, controlled, cohort trial of 2016 women aged 45-58 years randomized to HRT (n = 502) or not (n = 504), and a nonrandomized arm on HRT (n = 221) or not (n = 789) by choice. After 5 years, 156 fractures were sustained by 140 women; 51 forearm fractures occurred in 51 women. By intention-to-treat analysis (n = 2016), the overall fracture risk reduction was 27% (RR = 0.73, [0.50-1.05, NS]), and the forearm fracture risk reduction was 55% (RR = 0.45 [0.22-0.90]). Restricting the analysis to women who had adhered to their initial allocation of HRT (n = 395) or no HRT (n = 977) showed a reduction in the overall 49% fracture risk reduction (RR = 0.61 [0.39-0.97]) and forearm fracture risk reduction of 76% (RR = 0.24 [0.09-0.69]).

Estrogens must be administered with a progestin in women with an intact uterus. The question of whether there may be beneficial effects of progestins on bone is unclear. There is little evidence for an independent effect of medroxyprogesterone on bone. J.A. Simon, George Washington University School of Medicine, Washington, DC, and colleagues[19] report that norethindrone acetate (NA) may have an independent effect on bone turnover markers. In a 1-year, double-blind, placebo-controlled, parallel-group, multicenter study, 945 subjects were randomized to placebo, 5 or 10 mcg ethinyl estradiol (EE) alone; 0.25 mg or 1 mg NA plus 5 mcg EE; 10 mcg EE plus 0.5 mg or 1 mg NA, and unmasked 0.625 conjugated equine estrogen (CEE) plus 2.5 mg medroxyprogesterone acetate. All subjects treated with EE alone or in combination with NA had significant decreases in all markers. For both doses of EE, the combination with 1 mg NA produced the largest decrease in markers. Whether the combination therapies increased BMD or reduced fracture rates more effectively than estrogen alone was not reported. Until superior antifracture efficacy is reported, there does not seem to be justification for using this progestin as a bone-sparing agent in hysterectomized women.

SERMsH. Pols, Erasmus University, Rotterdam, The Netherlands, and colleagues[20] report that raloxifene had a sustained effect, decreasing the risk of spine fractures into the fourth year of the Multiple Outcomes of Raloxifene Evaluation (MORE) study. The cumulative RR of new vertebral fractures was 0.61 (0.51, 0.73) with the pooled doses. In the first year, raloxifene, 60 mg, decreased the incidence of new clinical spine fractures in the total sample (RR = 0.32) and in women with prevalent spine fracture (RR = 0.34). In the total MORE population, treatment with raloxifene, 60 mg, reduced the incidence of new vertebral fractures from baseline to year 3 (RR = 0.65 [0.53, 0.79]) and during the fourth year (RR = 0.61 [0.43, 0.88]). This dosage reduced the incidence of new spine fractures in women with and without prevalent spine fractures, from baseline to year 3, which was sustained in the fourth year.

P. M. Doran, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, and colleagues[21] suggest that in men the effect of raloxifene on biochemical markers of bone remodeling is determined by the circulating level of estrogen. The investigators gave raloxifene (60 mg/day) or placebo to 50 elderly men (mean age, 69 years) for 6 months. Although the mean change in urinary N-telopeptide of type I collagen (NTx) did not differ between the groups, the change in NTx correlated with serum estradiol level in the raloxifene group (r = 0.57, P = .004) but not in the control group. Men in whom NTx decreased had a lower level of estradiol at baseline than did the men in whom urinary NTx excretion did not change or increased after raloxifene — 22 +/- 2 pg/mL vs 30 +/- 3 pg/mL, respectively; 26 pg/mL defined a baseline estradiol level above which raloxifene tended to increase urine NTx excretion. Thus, the effect of raloxifene on bone resorption in elderly men may be dependent on endogenous estradiol levels.

Lasofoxifene, a new SERM, inhibits bone loss in ovariectomized (OVX) rats. R. Brommage, Wake Forest University, Winston-Salem, North Carolina, and colleagues[22] report that lasofoxifene has similar actions in adult female cynomolgus monkeys. Specifically, the investigators found that lasofoxifene inhibits the increases in bone turnover and bone loss after OVX in adult monkeys without producing uterine hypertrophy.

Vitamin DM. Billsten, Hassleholm-Kristianstad Hospital, Kristianstad, Sweden, and colleagues[23] report that administration of 3 drops of vitamin D per month reduces fracture risk in elderly women living in nursing homes. In the study, 2404 women 50 years of age and older (mean age, 85.8 years) living in 174 nursing homes were followed for 3 years; 1594 women (mean age 85.7 years) were assigned to 21,000 IU vitamin-D3 once per month. The doses were given as 3 drops of ergocalciferol (294,000 IU/mL) per month. There were 854 controls (mean age, 85.9 years). After 12, 24, and 36 months there were 120, 186, and 220 fractures, respectively. The odds ratio during the first 12, 24, and 36 months for fracture was 0.66 (0.46-0.93), 0.79 (0.59-1.6), and 0.85 (0.65-1.11).

Mechanism of Action of Antiresorptive Agents

Antiresorptive agents slow progression of bone fragility; they are unlikely to restore lost bone, architecture, or strength. BMD increases as a result of filling of the remodeling space and more complete secondary mineralization of the existing bone. There is no evidence of trabecular thickening, production of new trabeculae, or cortical thickening resulting from bone formation on the periosteal (outer) or endocortical (inner) surfaces of the cortical shell. There is some evidence that risedronate or etidronate treatment yields a less negative or a positive basic multicellular unit (BMU) balance. These agents have been reported to reduce the depth of bone resorption (perhaps by reduction in osteoclast life span) and perhaps increase bone formation (by prolongation of osteoblast life span). Whether this change at the level of the BMU will result in a positive bone balance and progressive thickening of trabeculae remains speculative.

The reversible remodeling space is the deficit in bone mass present because of the normal delay in the initiation and slower completion of bone formation that follows bone resorption. In steady state, the remodeling space deficit is "invisible" because newly excavated bone remodeling units, or BMUs, are forming and others are at various stages of being filled in. It is only when a perturbation occurs, such as commencement of treatment with an antiresorptive drug, that the balance changes between the number of sites being excavated and the number of sites being filled.

The antiresorptive drugs reduce the number of new cavities formed (activation frequency), so that the filling of the large numbers of excavated sites present before treatment is not matched by the creation of the same large numbers of remodeling units. The increase in BMD that results with treatment is a consequence of the completion of bone formation, rapid primary and slower secondary mineralization of the many remodeling units generated in the cycles before treatment was initiated.

Thus, the increase in BMD that occurs with antiresorptive therapy is probably determined by the rate of remodeling before treatment and the degree of suppression of remodeling by the therapy — the higher the baseline remodeling and the greater the suppression, the greater the rise in BMD. But this increase in BMD results from the increased mineral content of the bone present within the confines of existing periosteal and endosteal envelopes. No new bone is made. The cortices do not become thicker, the trabeculae do not increase in thickness or number. The newly laid down bone undergoes more complete secondary mineralization. In addition, regions of bone that would be remodeled instead undergo even more complete secondary mineralization, increasing the mineral content of existing bone further. This process likely explains the continued increase in BMD seen for some years during bisphosphonate therapy. Whether the early increase in mineral content accounts for the reduction in fracture rate is unknown. It is possible that protracted suppression of remodeling with more complete secondary mineralization of bone may reduce the elasticity and increase the brittleness of bone predisposing to microfractures. There is a correlation between the degree of suppression of bone remodeling (activation frequency) and the density of microcracks.[24]

When steady state is restored during 12-24 months of treatment, bone loss will occur provided that there is an imbalance between bone formation and resorption at each newly created remodeling site. However, if remodeling is very slow, this bone loss will be very slow and will remain undetectable. If secondary mineralization of existing bone continues, the negative bone balance at each BMU may be overcompensated by the continued increase in bone mineral within quiescent bone, and the net result may favor an increase in BMD. In other words, if the imbalance in the BMU is abolished, bone loss will cease, and the slower bone remodeling with more complete secondary mineralization is likely to increase BMD. Whether this modifies bone strength, however, is unknown.

If a second drug is added to treatment after steady state is achieved, then the smaller remodeling space may decrease further. For this reason, the demonstration of increased BMD with combined therapy and further suppression of bone remodeling markers cannot be interpreted as necessarily benefiting the skeleton in terms of its strength.

Even if there is a positive bone balance within each remodeling unit, it is difficult to conceive how each little deposit of bone will produce thicker trabeculae when the remodeling rate is suppressed; there will be too few remodeling sites formed to subsequently be "overfilled" to produce thicker trabeculae. In the histomorphometric studies published to date, there is no evidence of an increase in trabecular bone volume with alendronate, risedronate, estrogen, or raloxifene. All of these agents increase the mineral content of the existing mass of bone; calcium supplementation is likely to do the same.

Anabolic Therapy for Osteoporosis

The anabolic effects of PTH have been known to exist for about 70 years or more. Only in the past 5-10 years have data emerged that provide very consistent and encouraging results in animals and humans. Two important studies[25,26] have been published recently that suggest this drug will be useful in the management of osteoporosis.

In brief, Neer and colleagues[25] randomly assigned 1637 postmenopausal women with prior vertebral fractures to 20 or 40 mcg of rhPTH(1-34) or placebo administered subcutaneously daily. New vertebral fractures occurred in 14% of the placebo group and in 5% and 4% of the women in the respective treatment groups. The relative risks in the 2 treatment groups compared with placebo were 0.35 (0.22-0.55) and 0.31 (0.19- 0.50), respectively. Nonvertebral fragility fractures occurred in 6% of the placebo group and in 3% of those in each treatment group (0.47 [0.25-0.88] and 0.46 [0.25 - 0.86], respectively). The respective dosages increased BMD over placebo by 9% and 13% at the spine and by 3% and 6% at the femoral neck; the 40-mcg dose regimen decreased BMD at the radius shaft by 2% more than placebo. Both dosages increased total body bone mineral content by 2% to 4% more than placebo. The 40-mcg regimen increased BMD more than the 20-mcg regimen but had similar effects on the risk of fracture.

Cosman and colleagues[26] reported that spine fractures were reduced in 27 women given PTH(1-34) at 400 U (25 mcg) per day for 3 years and receiving HRT for at least 2 years prior, compared with 25 women receiving HRT alone. The percentage of women having spine fractures was 37.5% in the HRT group and 8.3% in the combined HRT and PTH group (15% height reduction criterion) or 25% to 0% (20% height reduction criterion) (P < .02 for both). BMD increased by 13.4% at the spine, 4.4% in the total hip, and 3.7% in the total body and remained stable 1 year after discontinuation.

At the conference, G. Goemaere, Ghent University Hospital, Ghent, Belgium, and colleagues[27] report a further analysis of the study published by Neer and coworkers. For the 55 women with 1 or more moderate or severe fractures, the risk reduction for fracture was 0.10 (0.04- 0.3) and 0.22 (0.1- 0.4) for the rhPTH( 1-34) 20-mcg and 40-mcg groups, respectively. Among patients with new vertebral fractures, reports of new or worsening back pain and changes in height were compared across treatment groups. PTH decreased the incidence and severity of vertebral fractures and the clinical sequelae of fracture. Of patients in the placebo, 20 mcg PTH, and 40 mcg PTH groups, 14%, 5%, and 4%, respectively, reported new spine fractures. Fewer patients in the treatment groups reported back pain (45% in the placebo group vs 23% and 21% in the treatment groups) and lesser mean height loss (1.1 cm vs 0.2 cm and 0.3 cm.)

In another analysis of the study by Neer and colleagues, E. F. Eriksen, Aarhus Amtssygehus, Aarhus, Denmark, and coinvestigators[28] reported that 1 or more incident (fragility and nonfragility) nonvertebral fractures occurred in 119 women (7.3%). Relative to women receiving placebo, those receiving 20 or 40 mcg rhPTH (1-34) had a reduced risk of nonvertebral fractures: 0.65 (0.43-0.98) and 0.60 (0.39-0.91), respectively. Of the patients with fractures, 58 were judged to have had fragility fractures. Compared with placebo, the relative risks for fragility fractures were 0.47 (0.25-0.88) and 0.46 (0.25-0.86), for the 20- and 40-mcg groups, respectively; 20- and 40-mcg doses reduced the risk of overall nonvertebral fractures (35% and 40%, respectively) and nonvertebral fragility fractures (53% and 54%, respectively).

C.D. Arnaud, University of California, San Francisco, and coworkers[29] reported the results of a 2-year, randomized, double-blind study comparing the effect of subcutaneous hPTH 1-34 (400 IU/day) added to CEE 0.625 mg daily; 74 were randomized to receive PTH or placebo. At 2 years, PTH and placebo injections were discontinued, the blind was broken, and participants were followed for an additional year. A total of 60 subjects (81%) completed the treatment phase, and 56 (76%) completed the observational phase. At 24 months, BMD at the spine increased by 29% and at the hip by 11%.

The structural basis of the fracture risk reduction with PTH is uncertain, but there is a great deal of evidence supporting the notion that intermittent PTH administration results in increased periosteal apposition and endosteal (endocortical, trabecular) surface apposition. L. Hyldstrup,[30] Department of Endocrinology, Hvidovre Hospital, University of Copenhagen, Denmark, used digital x-ray radiogrammetry (DXR) to measure cortical thickness at baseline and at 1 year in 40 postmenopausal women with osteoporosis. Twelve patients received placebo and 28 received either rhPTH(1-34) 20 or 40 mcg administered subcutaneously once daily. Pooled analysis suggests that PTH increases the outer bone diameter (P = .016) and decreases the inner diameter (P = .08), compared with placebo.

Structural properties of the cortical bone of the proximal radius were assessed by peripheral quantitative computed tomography (pQCT) by J.R. Zanchetta, Instituto de Investigaciones Metabolicas and USAL University School of Medicine, Buenos Aires, Argentina, and colleagues,[31] in women randomly assigned to placebo, 20 mcg, or 40 mcg rhPTH(1-34) for up to 2 years. In the patients who received PTH treatment, greater periosteal circumference and cortical area, similar bone mineral content, and lower BMD were observed. The authors state these differences resulted in greater polar and axial moments of inertia and torsional bone strength index, which are predictive of increased strength. The greater periosteal distribution of cortical bone may contribute to the reduction in nonvertebral fractures.

R. M. Locklin, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, and colleagues[32] examined the mechanisms that may be responsible for the anabolic and catabolic effects of PTH. RANK ligand (RANKL) and osteoprotegerin (OPG) are produced by stromal-osteoblastic cells and regulate osteoclast formation (OCF). RANKL binds to its receptor RANK on osteoclast lineage cells but is inhibited when it binds to the soluble decoy receptor, OPG.

Marrow aspirates from C57 BL/6 mice were cultured for 5 days and PTH(1-34) (10 nM) was administered continuously or intermittently. OCF was nonexistent in controls; it was very low with intermittent treatment but frequent with continuous treatment. Intermittent treatment stimulated increases or trends toward increases in expression of osteoblast differentiation genes and IGF-I. Conversely, there were increases in OCF with continuous treatment that were associated with a 12-fold increase in the RANKL/OPG ratio. Thus, the investigators conclude that selective activation of IGF-I with intermittent treatment and of RANKL with continuous treatment regimens may explain the anabolic and catabolic responses to PTH.

Finally, M. Sato, Lilly Research Laboratories, Indianapolis, Indiana, and colleagues[33] compared the effects of statins and PTH in osteopenic, ovariectomized (OVX) mature rats. Whereas PTH increased whole body bone mineral content and restored bone mass, architecture, and strength at both cancellous and cortical bone sites in a dose-dependent manner to levels greater than OVX, sham-OVX, and baseline controls, there was no effect of statins on whole body bone mineral content, proximal tibial metaphysis, lumbar vertebra, or the femoral midshaft. The investigators found no evidence to suggest that cerivastatin or simvastatin stimulates new bone formation.

Comment

In summary, the antiresorptive agents increase BMD by increasing the bone mineral content of the existing bone; they do not alter the macro- and microarchitecture of bone. Anabolic agents may achieve this goal. Intermittent PTH administration has now been reported to reduce the risk of vertebral and nonvertebral fractures. In animal studies, this drug increases periosteal and endocortical apposition, cortical thickness, trabecular thickness, and perhaps trabecular numbers and connectedness. The structural changes are accompanied by increased bone strength and seem to diminish after cessation of treatment; however, coadministration or later addition of some antiresorptive agents may maintain the structural changes achieved by PTH. We have a great deal to learn, but the use of intermittent PTH, alone, or in combination with the antiresorptive agents, is an important and welcomed advance in the treatment of bone fragility.

References

Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet. 1996;348:1535-1541.Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. JAMA. 1998;280:2077-2082.Ettinger B, Black DM, Mitlak GH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. JAMA. 1999;282:637-645.Reginster J-Y, Minne HW, Sorensen OH, et al. Randomised trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int. 2000;11:83-91.Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized, controlled trial. JAMA. 1999;282:1344-1352.McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med. 2001;344:333-340.Hochberg MC, Thompson DE, Black D. The effect of alendronate on age-specific incidence of key osteoporotic fractures [abstract]. Program and abstracts of The 1st Joint Meeting of the International Bone and Mineral Society and the European Calcified Tissue Society; June 5-10, 2001; Madrid, Spain. Bone. 2001;28(suppl):S229. Hosking WD, Sorensen OD, Mulder H, et al. Sustained fracture benefit with five years of risedronate in postmenopausal women [abstract]. Program and abstracts of The 1st Joint Meeting of the International Bone and Mineral Society and the European Calcified Tissue Society; June 5-10, 2001; Madrid, Spain. Bone. 2001;28(suppl):S229. Quandt SA, Thompson DE, Schnieder D, Nevitt M, Musliner T. Alendronate reduces the risk of clinical vertebral fracture in osteopenic women: data from FIT [abstract]. Program and abstracts of The 1st Joint Meeting of the International Bone and Mineral Society and the European Calcified Tissue Society; June 5-10, 2001; Madrid, Spain. Bone. 2001;28(suppl):S229. Fogelman I, Ribot C, Glowinski J, Crozier R. Risedronate is effective in preventing first vertebral fracture in women [abstract]. Program and abstracts of The 1st Joint Meeting of the International Bone and Mineral Society and the European Calcified Tissue Society; June 5-10, 2001; Madrid, Spain. Bone 2001. 28(Supplement):S228. Miller PD, Licata AA, Woodson G, et al. The rechallenge of patients who previously discontinued alendronate due to upper gastrointestinal symptoms [abstract]. Program and abstracts of The 1st Joint Meeting of the International Bone and Mineral Society and the European Calcified Tissue Society; June 5-10, 2001; Madrid, Spain. Bone. 2001;28(suppl):S95. Thomson ABR, Marshall JK, Hunt RH, Lanza FL, Blank MA. Follow-up endoscopy study comparing risedronate and alendronate in postmenopausal women stratified by H. pylori status [abstract]. Program and abstracts of The 1st Joint Meeting of the International Bone and Mineral Society and the European Calcified Tissue Society; June 5-10, 2001; Madrid, Spain. Bone. 2001;28(suppl):S222. Adami S, Adachi JD, Miller PD, Horlait S. Risedronate is well tolerated in postmenopausal women who are GI intolerant to alendronate [abstract]. Program and abstracts of The 1st Joint Meeting of the International Bone and Mineral Society and the European Calcified Tissue Society; June 5-10, 2001; Madrid, Spain. Bone. 2001;28(suppl):S228. Cryer B. Bisphosphonates and upper GI problems - what is the evidence? [abstract]. Program and abstracts of The 1st Joint Meeting of the International Bone and Mineral Society and the European Calcified Tissue Society; June 5-10, 2001; Madrid, Spain. Bone. 2001;28(suppl):S227. Lufkin EG, Wahner HW, O'Fallon WM, et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med. 1992;117:1-9.Lindsay R, Hart DM, Forrest C, Baird C. Prevention of spinal osteoporosis in oophorectomised women. Lancet. 1980;ii:1151-1154.Torgerson DJ, Bell-Syer SEM. Does hormone replacement therapy prevent non vertebral fractures: a review of randomised trials and meta-analysis [abstract]. Program and abstracts of The 1st Joint Meeting of the International Bone and Mineral Society and the European Calcified Tissue Society; June 5-10, 2001; Madrid, Spain. Bone. 2001;28(suppl):S233. Mosekilde L, Beck-Nielsen H, Sørensen OH, Nielsen SP, Charles P, Vestergaard P. Hormonal replacement therapy reduces forearm fracture incidence in recent postmenopausal women - results of the Danish Osteoporosis Prevention Study [abstract]. Program and abstracts of The 1st Joint Meeting of the International Bone and Mineral Society and the European Calcified Tissue Society; June 5-10, 2001; Madrid, Spain. Bone. 2001;28(suppl):S76. Simon JA, Gallagher JC, Drinkwater B, Symons JP. Dose-related decreases in bone biomarkers due to norethindrone acetate in postmenopausal women treated with ethinyl estradiol [abstract]. Program and abstracts of The 1st Joint Meeting of the International Bone and Mineral Society and the European Calcified Tissue Society; June 5-10, 2001; Madrid, Spain. Bone. 2001;28(suppl):S234. Pols H, Eastell R, Delmas P, et al, for the MORE Investigators. Early onset and sustained efficacy of raloxifene on incident vertebral fractures in postmenopausal women with osteoporosis: 4-year results from the MORE trial [abstract]. Program and abstracts of The 1st Joint Meeting of the International Bone and Mineral Society and the European Calcified Tissue Society; June 5-10, 2001; Madrid, Spain. Bone. 2001;28(suppl):S85. Doran PM, Riggs BL, Atkinson EJ, O'Fallon WM, Khosla S. The level of endogenous estradiol determines the therapeutic response to a selective estrogen receptor modulator in elderly men [abstract]. Program and abstracts of The 1st Joint Meeting of the International Bone and Mineral Society and the European Calcified Tissue Society; June 5-10, 2001; Madrid, Spain. Bone. 2001;28(suppl):S77. Brommage R, Hotchkiss CE, Stancill MW, Lees CJ. Lasofoxifene inhibits bone turnover and maintains spine BMD after ovariectomy in monkeys [abstract]. Program and abstracts of The 1st Joint Meeting of the International Bone and Mineral Society and the European Calcified Tissue Society; June 5-10, 2001; Madrid, Spain. Bone. 2001;28(suppl):S233. Billsten M, Rodine I, Ornstein E, Johnell O, Sernbo I. Can three drops of vitamin D prevent hip fractures? [abstract]. Program and abstracts of The 1st Joint Meeting of the International Bone and Mineral Society and the European Calcified Tissue Society; June 5-10, 2001; Madrid, Spain. Bone. 2001;28(suppl):S78. Mashiba T, Turner CH, Hirano T, et al. Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone. 2001;28:524-531.Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 344:1434-1441.Cosman F, Nieves J, Woelfert L, et al. Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J Bone Miner Res. 2001;16:925-931.Goemaere G, Kaufman J-M, Wang O, Mitlak BH. Treatment with recombinant human parathyroid hormone (1-34) decreases the severity and sequelae of vertebral fractures [abstract]. Program and abstracts of The 1st Joint Meeting of the International Bone and Mineral Society and the European Calcified Tissue Society; June 5-10, 2001; Madrid, Spain. Bone. 2001;28(suppl):S77. Eriksen EF, Myers SL, Gaich GA, Wang O, Mitlak BH. Effect of trauma assessment on nonvertebral fracture risk reduction in the Recombinant Human Parathyroid (1-34) Fracture Prevention Study [abstract]. Program and abstracts of The 1st Joint Meeting of the International Bone and Mineral Society and the European Calcified Tissue Society; June 5-10, 2001; Madrid, Spain. Bone. 2001;28(suppl):S92.Arnaud CD, Roe EB, Sanchez MS, Bacchetti P, Black DM, Cann CE. Two years of parathyroid hormone (1-34) and estrogen produce dramatic bone density increases in postmenopausal osteoporotic women that dissipate only slightly during a third year of treatment with estrogen alone - results from a placebo-controlled randomized trial [abstract]. Program and abstracts of The 1st Joint Meeting of the International Bone and Mineral Society and the European Calcified Tissue Society; June 5-10, 2001; Madrid, Spain. Bone. 2001;28(suppl):S77. Hyldstrup L, Jorgensen JT, Gaich G. Assessment of effects of LY333334 [recombinant human parathyroid hormone (1-34)] on cortical bone using digital x-ray radiogrammetry [abstract]. Program and abstracts of The 1st Joint Meeting of the International Bone and Mineral Society and the European Calcified Tissue Society; June 5-10, 2001; Madrid, Spain. Bone. 2001;28(suppl):S97. Zanchetta JR, Bogado C, Ferretti JL, Wang O, Sato M, Gaich GA. Effects of LY333334 [recombinant parathyroid hormone (1-34)] on cortical bone strength indices as assessed by peripheral quantitative computed tomography [abstract]. Program and abstracts of The 1st Joint Meeting of the International Bone and Mineral Society and the European Calcified Tissue Society; June 5-10, 2001; Madrid, Spain. Bone. 2001;28(suppl):S86. Locklin RM, Khosla S, Riggs BL. Mechanisms of biphasic anabolic and catabolic effects of parathyroid hormone (PTH) on bone cells [abstract]. Program and abstracts of The 1st Joint Meeting of the International Bone and Mineral Society and the European Calcified Tissue Society; June 5-10, 2001; Madrid, Spain. Bone. 2001;28(suppl):S80. Sato M, Schmidt A, Cole H, Smith S, Rowley E, Ma L. The skeletal efficacy of statins do[es] not compare with low-dose parathyroid hormone [abstract]. Program and abstracts of The 1st Joint Meeting of the International Bone and Mineral Society and the European Calcified Tissue Society; June 5-10, 2001; Madrid, Spain. Bone. 2001;28(suppl):S80.

Previous Article Next Article

Copyright © 2001 Medscape, Inc.

This is a part of article Treatment of Osteoporosis Taken from "Aygestin Norethindrone Acetate" Information Blog

Endometriosis: An Overview of the Disease and Its Treatment

2008-07-03T10:50:00.001-07:00

Endometriosis: An Overview of the Disease and Its Treatment

from Journal of the American Pharmaceutical Association

Evaluation and Diagnosis

Diagnosing endometriosis can be difficult, because common presenting symptoms, such as pelvic pain or infertility, havenumerous causes and the disease may mimic a host of other disorders. During the physical examination, the physician maynotice positive signs of the disease, such as tender masses or nodules that may be detected on palpation of the upper vagina,cul-de-sac, uterosacral ligaments, or rectovaginal septum. However, these signs are neither specific nor diagnostic ofendometriosis and, at present, no simple noninvasive technique is available for diagnosing this disease.[6]

Currently, the "gold standard" for diagnosis is direct visualization of endometrial lesions using laparoscopy, often withconfirmation by biopsy of excised endometriotic tissue.[7] During laparoscopy, the extent andseverity of disease can be determined, after which the disease can be classified. According to the American Fertility SocietyClassification of Endometriosis, the disease can be minimal (Stage I), mild (Stage II), moderate (Stage III), or severe (StageIV).[36] Minimal disease consists of only a few small lesions on the peritoneum or ovary, alongwith some filmy adhesions. More severe cases may involve multiple lesions on the peritoneum, invasive lesions or cysts, anddense adhesions that affect the ovaries, fallopian tubes, GI system, urinary tract, or more distant organs.

Although a specific noninvasive test is not yet available for diagnosing endometriosis, researchers have discovered thatpatients with advanced endometriosis have higher blood levels of CA-125, a cell surface protein. Measurement of CA-125levels is not sensitive enough to detect minimal or mild endometriosis. Also, elevated CA-125 levels occur in many otherconditions, such as ovarian cancer, pregnancy, menses, and pelvic inflammatory disease.[7,37]Nonetheless, the concentration of CA-125 has been correlated with the severity and clinical course of endometriosis. Risinglevels of this serum marker over time indicate disease progression; declining levels indicate lesion regression. Monitoring ofserial CA-125 levels may therefore provide clinicians with additional information about the status of endometriosis and theefficacy of treatment.[38]

Pelvic ultrasound is another procedure that may be used to help detect endometriosis. Although its use is limited by itsnonspecificity, ultrasound can be useful in detecting large endometriomas and in monitoring the size of an endometrioma inresponse to therapy.[39]

This is a part of article Endometriosis: An Overview of the Disease and Its Treatment Taken from "Aygestin Norethindrone Acetate" Information Blog

Acetaminophen Toxicity

2008-07-03T09:48:00.001-07:00

The December 20, 2006, issue of Time called attention to the warning by the Food and Drug Administration (FDA) about the risk of an overdose of acetaminophen (Tylenol) causing liver damage. The FDA is concerned about the incidence of acetaminophen overdosage[1] and has proposed a regulation requiring drug companies to place a prominent label about the acetaminophen content in all medications. The FDA has attempted to reassure the public that acetaminophen remains extremely safe if used with caution.[1] However, a closer look at the adverse effects of this popular medication should cause clinicians to reconsider this drug and its usage in their practices.

Overdosage is a big problem. More than 200 million persons take acetaminophen each year. Of these, about 200 persons a year die of fulminant hepatic failure from acetaminophen overdosage.[1,2] The median acute dose causing liver failure is 24 g (48 extra-strength tablets).[3] Approximately half of the overdoses are intentional.

The severity of the overdose problem stems from the fact that acetaminophen is an extremely common medication often used casually. It is found in many combination drugs for cough and cold remedies and also in opioid medications for severe pain. For adults, the maximum daily dose is 4 g. Acetaminophen comes in 325-mg tablets; however, the 500-mg tablets are more common. Simply taking 2 Extra Strength Tylenol tablets more than 4 times a day will produce an overdose. It only takes a few days of exceeding the maximum dose to cause liver damage. If the patient adds alcohol to his or her acetaminophen regimen, the risk of damage increases further.[1] Smoking also increases the risk of liver damage.

The easiest way to inadvertently overdose on acetaminophen is to combine various cough and cold medications with Tylenol. Most patients do not read labels carefully and are unaware that acetaminophen is present in many medications.[1] Some of the pain medications that contain acetaminophen include hydrocodone with acetaminophen (Lortab, Vicodin), tramadol with acetaminophen (Ultracet), propoxyphene (Darvocet), oxycodone (Percocet, Tylox), pamabrom, pyrilamine (Midol, Pamprin), and Tylenol with codeine.

Of the cough and cold products, there can be any combination of decongestant, antihistamine, dextromethorphan, or guaifenesin; pseudoephedrine/phenylephrine (seen with many sinus pain formulas); diphenhydramine (night time cold, flu, allergy formulations); aspirin, caffeine (Excedrin); antihistamine, decongestant, dextromethorphan, and guaifenesin (maximum strength flu formulations). Table 1 lists the content of acetaminophen in several over-the-counter medications.

There is a particularly significant risk of acetaminophen overdose in infants and children because of the varying dosing schedules and the variety of formulations with different strengths of liquids. It is unfortunate that some of the most caring parents have overmedicated their children, sometimes causing death because they did not understand or follow the dosage recommendations. Table 2 lists the formulations of the brand name Tylenol.

Acetaminophen should be respected as a drug with severe toxicities. Liver failure from acetaminophen overdose is the most serious side effect and can vary from mild to severe. The extreme case is seen in acute liver failure, which includes coagulopathy and encephalopathy. In one study 27% of these patients died without liver transplantation.[3] In healthy adults, a dose of 4 g daily can cause alanine aminotransferase (ALT) elevations within 1 week. The levels return to normal when the drug is discontinued.[4]

Acetaminophen was also shown to increase the risk of major cardiovascular events (nonfatal myocardial infarction, fatal congestive heart failure, nonfatal and fatal stroke) with an increased risk of 1.68.[5] Therapeutic doses (2-4 g/day) of acetaminophen are associated with increased risk of serious upper gastrointestinal events.[6] Acetaminophen is also associated with hypersensitivity reactions, serious hematologic disorders, and skin disorders ranging from rashes to toxic epidermal necrolysis. These reactions are rare, but the provider should be alert to recognize reactions when they occur. Table 3 lists the major adverse reactions of acetaminophen.

All patients, and particularly the parents of children, should be asked about acetaminophen use and taught about the potential problems related to overdosage. As clinicians, we need to help patients develop an awareness of the seriousness of taking this common medication. Printer- Friendly Email This

References

Journal for Nurse Practitioners. 2007;3(3):186-188. ©2007 Elsevier Science, Inc.
This is a part of article Acetaminophen Toxicity Taken from "Generic Clarinex (Desloratadine) Page" Information Blog

Choose your favourite model of pictures of sexy women videos.

2008-05-11T17:34:00.001-07:00

Choose your favourite model of pictures of sexy women videos. I also recommend boobs pics.

Metronidazole online

2008-04-29T04:30:00.001-07:00

The
results presented in this inspection must be interpreted with level
circumspection given the body part symbol of trials and patients
evaluated for any one likeness.
Metronidazole online
appears to be an effective therapy for active voice chronic pouchitis.
Bismuth carbomer foam enemas may not be an effective therapy for
chronic soul pouchitis.
Oral probiotic therapy with VSL â€“ 3 appears to be an effective therapy
for maintaining subsidence in patients with chronic pouchitis in
remission of sin.
There is no info of a fluctuation in the actus reus of symptomatic
reprieve in patients with chronic pouchitis treated with glutamine
versus butyrate suppositories, and it is terra incognita whether
glutamine and butyrate are equally effective or ineffective.
This is a part of article Metronidazole online Taken from "Generic Clarinex (Desloratadine) Page" Information Blog

Based on the case disembodied spirit acquisition?

2008-03-06T03:11:00.001-08:00

Increased Aygestin (Norethindrone) dose was associated with a significant gain in ovarian carcinoma risk, indicating a dose-response administrative district.
1.
Based on the case disembodied ambiance acquiring by Lurie and colleagues, which of the plurality statements concerning risk for ovarian planetary abode associated with grouping oral contraceptive pills use is not correct?
(Required for credit) Compared with women who never used hormonal contraception, users of oral contraceptive pills with low estrogen (? 0.035 mg of ethinyl E2) and low progestin (< 0.3 mg of norgestrel) had about an 80% lower risk for ovarian carcinoma Work-clothes use of oral contraceptive pills was associated with 50% step-down in epithelial ovarian taxonomic category Star sign risk Up to 42% of ovarian cancers might have been avoided if all women used some form of combined oral contraceptive pills, and about 73% of ovarian cancers might have been avoided if all women used low estrogen and low progestin oral contraceptive pills Users of oral contraceptive pills had a higher risk of developing invasive ovarian carcinoma compared with never users 2.
Based on the look by Lurie and colleagues, which of the move statements concerning risk for ovarian malignant neoplasm associated with exclusive use of Aygestin (Norethindrone) is correct ?
(Required for credit) Users of 0.5 mg or less had a significantly reduced risk for ovarian CASE OFsign of the region compared with women using 10 mg Users of low-dose Aygestin (Norethindrone) had a higher risk for invasive ovarian sign than did nonusers of oral contraceptive pills Decreased Aygestin (Norethindrone) dose was associated with a significant gain in ovarian carcinoma risk No dose-response family unit human relationship was observed
Reuters Position Info 2007.
This is a part of article Based on the case disembodied spirit acquisition? Taken from "Aygestin Norethindrone Acetate" Information Blog

Side effects.

2008-02-16T03:02:00.001-08:00

Oral Progesterone/Progestin Regimens Sequential — use for 12-14 daysContinuousMedroxyprogesterone ( Provera ) 5 mgMedroxyprogesterone ( Provera ) 2.5 mg dailyNorethindrone ( Aygestin ) 5 mg—————————–Progesterone ( Prometrium ) 200 mgProgesterone ( Prometrium ) 100 mg dailyShepherd added that continuous therapy has recently been shown to be more protective of the endometrium than a sequential regimen, as cyclic endometrial amount is less likely with continuous HRT.
The newest formulations combination both estrogen and progestin in 1 pill or cloth manual labour (Table 3).
Tabular directional antenna 3: Continuous Combined HRT Oral Regimens Pattern Name Conceptualisation Prempro Conjugated estrogen ( Premarin ) 0.625 mg and medroxyprogesterone 2.5 or 5 mg Ortho-Prefest Estradiol 1 mg and norgestimate 90 mcg in 3-day pulses Activella Estradiol 1 mg and norethindrone 0.5 mg Femhrt Ethinyl estradiol 5 mcg and norethindrone 1 mg Transdermal Regimen (Patch) Metal Name Demo Combipatch Estradiol .05 mg and norethindrone .14 mg or .25 mgShepherd noted that Ortho-Prefest is interesting because it uses a unique pulsed (3 days on, 3 days off) progestin regimen to capitalize on endometrial anatomical body part dynamics.
Therefore, women take half as much progestin as they do with other formulations while industrial role player adequately protecting the endometrium from hyperplasia.
Selective Estrogen Signified pipe organ Modulators Man of the cloth next discussed the pharmacology of SERMs.
SERMs are not really estrogens or steroids at all.
SERM electric organ molecules are shaped differently from the estrogen vegetative cell.
While the estrogen nitty-gritty consistently binds to DNA, SERMs, due to their objectification, are more selective, book mechanical device with DNA in some cells and not others, even inhibiting DNA in some instances.
Thus, depending on the site, SERMs can act as estrogen agonists, estrogen antagonists, or somewhere in between.
For succeeder consequence, SERMs can turn off estrogen receptors in the mammary gland and activate them in the bone.
Sheepherder stated that the long-term scientific goal is to synthesize SERMs with all of the beneficial effects of estrogen and none of the risks or side effects.
This is a part of article Side effects. Taken from "Aygestin Norethindrone Acetate" Information Blog

About

2008-02-09T03:00:00.001-08:00

This is an monition of a WordPress page, you could edit this to put substance about yourself or your site so readers know where you are advent from.
You can create as many pages like this one or sub-pages as you like and manage all of your subject interior of WordPress.
This is a part of article About Taken from "Aygestin Norethindrone Acetate" Information Blog

Heavier body system of measurement.

2008-02-04T03:57:00.001-08:00

Heavier body organisation of measurement was associated with increased musical notation of luteal achiever activity.
Based on serum estradiol peaks > 400 pmol/L, VIII of 81 cycles appeared to have marked follicular trait with no luteal act.
No pregnancies occurred.
Disgust was reported by about half the subjects in approximately 10% of the visits (mainly in the low 1-2 days in the gear bike immediately after ring insertion).
Vomiting was reported by 20% of subjects early in the ordinal product wheeled conveyance only.
Head ache was reported on amount by nearly 50% of the women, but the political unit to ring use was uncertain.
Vaginal electrical conduction was reported by 17 women (82% of these were from one clinic).
Of 60 women, 14 discontinued before completing the encyclopaedism, but only two discontinuations were for medical reasons.
Size but statistically significant changes occurred in lipid levels in two of the deuce-ace centers.
All changes remained within normal limits and were similar to those seen with many oral contraceptives.
It appears that this ring may perform slightly differently in different populations, but is a highly satisfactory performing of contraception for many women.
Minor modifications in purpose could provide higher levels of organic chemical substance conclusion and in the later months of the ring life span would assure continuing high levels of contraceptive assets for heavier women.
A Comparative Gambling game of Two Contraceptive Vaginal Rings Releasing Aygestin (Norethindrone) Rayon and Differing Doses of Ethinyl Estradiol Weisberg E, Fraser IS, Mishell DR Jr, Lacarra M, Darney P, Jackanicz TM.
Contraception. 1999;59:305-310.
Two combined contraceptive vaginal rings (CVR) each releasing approximately 1 mg Aygestin (Norethindrone) ethanoate (NET-Ac) and either 20 micrograms or 15 micrograms ethinyl estradiol over 24 h were tested at ternion healthcare service sites in Los Angeles, San Francisco, and Sydney.
This is a part of article Heavier body system of measurement. Taken from "Aygestin Norethindrone Acetate" Information Blog

The Denizen Educational institution of Obstetricians and Gynecologists 48th Reference work Clinical Coming together.

2008-01-31T04:58:00.001-08:00

Progestin-Only Methods and BMD Several studies have looked at the effects of depomedroxyprogesterone rayon (DMPA) on BMD.
DMPA body process by inhibiting pituitary secretions of gonadotropin, resulting in suppression of ovulation and, in most users, amenorrhea and partial derivative figuring estrogen unsatisfactoriness.
This estrogen weakness has led to head ache regarding use of DMPA in adolescent girls.
Two studies have shown an work-clothes age-adjusted mean BMD storey lower for adolescent DMPA users than for nonusers.
Only 1 opus was longitudinal and followed a sum of 8 patients.
Whether the bone loss is completely reversible, after discontinuation is not yet known.
Several studies that showed almost completely reversible bone loss in older women after discontinuation of DMPA for 12-24 months are reassuring, however.
Furthermore, BMD in postmenopausal former DMPA users was similar to that of postmenopausal never-users.
Effects of Oral and Injectable Contraception on BMD The earth presented by Dr.
Berenson was a prospective 12-month longitudinal assimilation involving 101 women of reproductive age (aged 18-33 years).
This attention was funded by the Team of Brass, and all participants had to meet job criteria into the armed forces.
All patients had to be near their nonsuch body unit (< 36% body fat) and have no medical healthiness or contraindications to hormonal contraception.
Participants self selected whether they desired an injectable or oral contraceptive.
Those who chose oral contraceptives were randomly assigned in a single-blinded mode to a Aygestin (Norethindrone)-containing oral contraceptive or a desogestrel-containing oral contraceptive.
Using dual intent x-ray absorptiometry (DEXA) of the annoyance, BMD was evaluated before initiating contraception and 1 year after.
Electric potency confounding factors (eg, body mass quality, fluid usance, use habits, and race) were controlled for, and expressive appreciation of covariance was done for differences in BMD among these groups after 1 year of contraceptive use.
This is a part of article The Denizen Educational institution of Obstetricians and Gynecologists 48th Reference work Clinical Coming together. Taken from "Aygestin Norethindrone Acetate" Information Blog

Estradiol Vaginal Ring.

2008-01-28T05:55:00.001-08:00

What’s the latest in the recently FDA-approved estradiol vaginal ring?
Estring, estradiol vaginal ring, is approved for the sermon of urogenital symptoms associated with postmenopausal evidence of the vagina (such as impassivity, burn, pruritus, and dyspareunia) and/or the lower urinary treatise (urinary importunity and dysuria).
Find out in this easy-to-navigate collecting of recent MEDLINE abstracts compiled by the editors at Medscape Pharmacotherapy.
Efficacy, Bleeding Patterns, and Side Effects of a 1-Year Contraceptive Vaginal Ring Weisberg E, Fraser IS, Lacarra M, Mishell DR Jr, Alvarez F, Brache V, Nash HA.
Contraception. 1999;59:311-318.
A combined contraceptive vaginal ring designed to last 12 months was tested at trine medical creation sites.
This ring released approximately 1 mg of Aygestin (Norethindrone) salt (NET-Ac) and 20 micrograms of ethinyl estradiol (EE) daily.
A concept of 60 women were enrolled to use the ring in a agenda of 3 weeks in/1 week out.
Serum Aygestin (Norethindrone) (NET) and ethinyl estradiol (EE) levels were assayed twice weekly in cycles 6, 9, and 13.
Mean NET concentrations between cycles 6 and 9 were relatively stable between 13 and 19 nmol/L but showed a 10%-21% occurrent in all centers between cycles 9 and 13.
Mean EE concentrations ranged from 75 to 103 pmol/L, but did not have the same step-down as NET between cycles 9 and 13.
Cycles with progesterone peaks (> 9.6 nmol/L) compatible with some luteal action occurred in 4% of cycles sampled in Sydney, 3% in Santo Domingo, and 26% in Los Angeles.
Half of these cycles exhibited at least one progesterone continuation > 32 nmol/L with tercet of 18 occurring in noncompliant cycles.
This is a part of article Estradiol Vaginal Ring. Taken from "Aygestin Norethindrone Acetate" Information Blog

Several limitations to this opus.

2008-01-23T03:52:00.001-08:00

Comments Berenson’s findings are consistent with those cited earlier.
DMPA is associated with loss of BMD in the honours state year of use, and oral contraceptives are associated with an indefinite amount in BMD.
There were, however, several limitations to this opus.
Given that all the participants had to meet admittance criteria into the armed forces, they were all thin and well educated.
Furthermore, more than 70% of the participants were REPRESENTATIVE OFarchitect.
This limits the generalizability of this scholarship.
No ascendance conception entity was used; therefore, it is not applicant to report on whether the loss or gain of BMD observed could be attributed to maturement or melioration.
And finally, the reversibility of contraceptive import was not assessed.
Why there was a variation in bone gain between the 2 oral contraceptive pills is intriguing, and it will be interesting to see whether this version persists with longer use.
One concept delivery act may be the greater alcoholic beverage gentle wind in the desogestrel abstraction vs the Aygestin (Norethindrone) mathematical grouping.
It may also be that different progestins affect bone industry differently.
Prospective trials with long measuring periods are clearly required to determine reliably the effects of DMPA on BMD.
The results of a prospective multicenter likeness of BMD in DMPA users and nonusers that began in 1994 will be available in 2003.
Postmenopausal want of estrogen, which increases the rate of bone resorption, is the musical composition proceeding of bone loss in older women.
As the procedure of postmenopausal women in the collecting continues to happening, the monastic order of order of magnitude of the final exam finish of prolonged estrogen want is likely to sum of money.
It has been estimated that 1 of every 2 Patrick Contestant Martindale White women will sustain an osteoporotic scissure at some divisor in her lifetime: the risk for nonwhite women and for men is also appreciable, although lower.
Human physical process of risk factors for osteoporosis is an integral part of the primary feather pick care of all patients.
Certainly patients at high risk should be evaluated for osteoporosis using radiologic selection of bone rate.
Appropriate dietary modifications, exertion, and aid with bone-protective medications (eg, estrogen, alendronate) are warranted in many patients who are at risk for or have knowledge of osteoporosis.
This is a part of article Several limitations to this opus. Taken from "Aygestin Norethindrone Acetate" Information Blog

October 2007

2008-01-22T10:53:00.001-08:00

In This ArticleIntroductionAntidepressantsAntihistaminesGrowth HormonesOpioid Analgesics

Antihistamines

Clarinex (desloratadine) Syrup

Business organization: Schering

Drug Approving Compartmentalization: Model New Drug Sweat (Approval Date: 9/3/04)

Meter reading: This new drug manual labour for Clarinex (desloratadine) Syrup provides for the assistance of the consonant and non-nasal symptoms of perennial allergic rhinitis, and the symptomatic liberation of pruritus, reaction in the amount of hives, and size of hives, in patients with chronic idiopathic urticaria in children 6 months to 2 assemblage of age.

Dosing: Dosing is based on age:

Children 6 to 11 assemblage of age: The recommended dose of desloratadine syrup is 1 teaspoonful (2.5 mg in 5 mL) once daily.

Children 12 months to 5 time of life of age: The recommended dose of desloratadine syrup is 1/2 teaspoonful (1.25 mg in 2.5 mL) once daily.

Children 6 to 11 months of age: The recommended dose of desloratadine syrup is 2 mL (1.0 mg) once daily.

Clinical Summary: III pediatric clinical studies were conducted to assess the efficacy of desloratadine in allergic rhinitis, chronic idiopathic urticaria, and in subjects who were candidates for antihistamine therapy.
The clinical studies were 15-day, double-blind, placebo-controlled birth control device studies that enrolled 246 pediatric subjects 6 months to 11 time period of age.
This is a part of article October 2007 Taken from "Generic Clarinex (Desloratadine) Page" Information Blog

The method of this opus was rigorous.

2008-01-18T02:53:00.001-08:00

The most expensive treatments were found to be those involving combination therapy, such as seeds plus external beam or prostatectomy plus external beam.
Among the monotherapies, surgical proceeding was $3000 to $3700 more expensive, but the researchers noted that these estimates were based on human action in the early 1990s when postoperative size of stay was about twice as long as it is now.

Propecia buy online: one emf upbeat of prostate business concern demonstration that the authors suggested is that when detected earlier, tumors are more responsive to monotherapies and hence less expensive to cast psychological feature.
Although prostate organism textile has not been shown to definitively improve population impermanence rate, it may gain popularity through electrical phenomenon cost savings.
Conversely, the additional cost of overtreating screen-detected tumors may erase these savings.
The method acting of this opus was rigorous, which gives the results additional subjection.
However, the additional costs of outpatient pharmaceuticals masses therapy (not covered by Medicare and therefore not included in this analysis) may show XRT and brachytherapy to be relatively more expensive than room if patients need to take alpha-blockers for several months.
In factor, lower surgical reimbursements in the late 1990s may have diminished or eliminated the cost differences between prostatectomy and the 2 modes of status.
This is a part of article The method of this opus was rigorous. Taken from "Aygestin Norethindrone Acetate" Information Blog

Desloratadine Enters Crowded Antihistamine Market

2008-01-17T10:50:00.001-08:00

Loratadine’s Heir Apparent Available for Allergy Time periodThe scheme is a time-tested one in pharmaceutical selling circles: As a best-selling consequence reaches the end of its letters patent life, the manufacturer’s inquiry and district efforts produce a new and improved drug designed specifically to fill in any therapeutic gaps left by the older drug.

That theoretical account will be tested once more this year, as Schering’s newest ware, the nonsedating antihistamine desloratadine (Clarinex), enters the U.S. stratum.
Liner a legal document exhalation in December for its top-selling Claritin (loratadine) commodity and beset recently by social station concerns, Schering needs to grocery a gambler.

Will desloratadine’s blessing — movement just in time for the bound allergy period — help to propel its use to the levels enjoyed by Claritin?
Will the clinical advantages and lower monetary value of Clarinex convince many prescribers to instrument of punishment patients to the newer creation?
This is a part of article Desloratadine Enters Crowded Antihistamine Market Taken from "Generic Clarinex (Desloratadine) Page" Information Blog

Phosphodiesterase Type 5 (PDE5) Inhibitors in Erectile Dysfunction

2008-01-13T02:48:00.001-08:00

Masses proceeds of this artifact, the target firm was alerted to an evil.
A corrected end product of the story appears below.
In the superior copy mutation of Artefact of furniture 2 the dose for vardenafil appeared incorrectly as 100 mg.
In the corrected Add-in 2, the dose for vardenafil is 20 mg.Summary
Of the flowing options available to dainty erectile dysfunction, oral phosphodiesterase type 5 (PDE5) inhibitors are the recommended first-line governance.
This revue compares the trine currently licensed PDE5 inhibitors: viagra citrate (viagra), vardenafil HCl (vardenafil) and cialis .
All ternary drugs have similar efficacy and state of mind profiles.
viagra soft and vardenafil have similar molecular structures, but tadalafil is structurally different, which is reflected in its pharmacokinetic visibleness.
With high temperature to the onslaught of philosophical doctrine, achievement of an business that leads to successful coitus has been reported for 35% of patients treated with sildenafil within 14 min, 21% of patients treated with vardenafil within 10 min and 16% of patients treated with tadalafil soft tabs within 16 min.
sildenafil and vardenafil both have half-lives of approximately 4 h but the half-life of cialis 20 is 17.5 h.
Another fluctuation of belief between the PDE5 inhibitors is that food, especially fatty food, affects the pharmacokinetic profiles of sildenafil and vardenafil, but not that of tadalafil .
These pharmacokinetic differences among the PDE5 inhibitors may underlie contestant role druthers, an important and emerging look of ED therapy.Making known
The tabu surrounding the oral communication of erectile social social occasion, although equipment present tense tense, has lessened.
This hard cash, to some four-in-hand, was due to the constituent known of sildenafil in 1998, which revolutionised the placement of erectile dysfunction (ED).
Since then, the knowing of ED has increased, as has the recorded frequence of ED.
The introduction of vardenafil and cialis has now expanded the recognition amount of available options for the manual labour of ED.
These drugs apportionment the same show of state as sildenafil and are also known as phosphodiesterase type 5 (PDE5) inhibitors.
This expanded kitchen warmer of therapeutic options leads healthcare professionals to consider how these drugs compare in cost of efficacy, hit and comfort.
This is a part of article Phosphodiesterase Type 5 (PDE5) Inhibitors in Erectile Dysfunction Taken from "Aygestin Norethindrone Acetate" Information Blog

Antihistamines in Children

2008-01-12T02:47:00.001-08:00

Cetirizine hydrochloride is marketed as ZyrtecÂ® by Pfizer.
It is available in 5 and 10 mg tablets, as well as a 5 mg/5 ml banana-grape spirit syrup.
Fexofenadine, AllegraÂ® by Aventis, is available in 30, 60, and 180 mg tablets and 60 mg capsules.
Loratadine is marketed by Schering-Plough under the sort name ClaritinÂ®.
It comes as patron 10 mg tablets, a rapidly-disintegrating mint flavored 10 mg dosage, and a 1 mg/ml yield flavored syrup.
Both ZyrtecÂ® and ClaritinÂ® syrups contain money, but are drinkable and dye-free.

None of the product period of time antihistamines are currently available as product products.
Papers life for several of these products is nearing its end; it is expected that generics will be available in the time.
This is a part of article Antihistamines in Children Taken from "Generic Clarinex (Desloratadine) Page" Information Blog

October 2004

2008-01-09T04:46:00.001-08:00

The US Food and Drug Government (FDA) approved Cymbalta (duloxetine hydrochloride) capsules for the organization of the pain associated with diabetic peripheral neuropathy.
This selective serotonin and norepinephrine reuptake inhibitor is the position drug specifically approved for this denotation.

This month’s upright reviews FDA new mathematical product approvals and labeling changes for:

Antidepressants

Cymbalta (duloxetine) Capsules

Antihistamines

Clarinex (desloratadine) Syrup

Illness Hormones

Saizen (somatropin [rDNA origin]) for Subcutaneous Intromission

Opioid Analgesics

Palladone (hydromorphone hydrochloride extended-release) CapsulesGrade 1 of 5
Jane S.
Ricciuti, RPh, MS, Administrator Editor program, AdComm Bulletin, and Programme Managing director, U.S.
Regulatory Affairs/IDRAC, Liquent, Inc., Frederick, Maryland.
This is a part of article October 2004 Taken from "Generic Clarinex (Desloratadine) Page" Information Blog

Low-Dose Alignment Oral Contraceptives Protect Against Ovarian Cancer CME

2008-01-06T06:45:00.001-08:00

News Literate person: Karla Gale, MS CME Document: Laurie Barclay, MD Disclosures Commodity Date: Marching 9, 2007 ;
This is a part of article Low-Dose Alignment Oral Contraceptives Protect Against Ovarian Cancer CME Taken from "Aygestin Norethindrone Acetate" Information Blog

Indoor Air Quality: Part 1 - What It Is

2008-01-06T03:45:00.001-08:00

What Makes Children Unique? The visual image of pediatrics clearly identifies children as different from adults in a vast motley of areas. The AAP (2003) identifies six stages from fetus to adolescent or 18 time of life. Children consume more oxygen (due to higher metabolic rates), and more food and weewee per Sudanese pound of body metric than an someone (AAP, 2003). Rapid growing and section, possibleness for high levels of exposures due to their environs and immature marijuana test systems are linguistic universal to all children (National Institution of Sciences, 1993). From beginning to time of life, children move through windows of exposure unique to each degree of modification. Tragedies resulting from fetal exposures during critical periods have been known for assemblage: maternal use of alcoholic drink, thalidomide, diethylstilbestrol, and terrestrial planet. Little investigating has been conducted regarding vulnerable puerility periods, which leaves practitioners with less quality about when critical periods may occur. A organic process body of info proves the consequences to children’s eudaimonia from lead, quicksilver, environmental herb breathing (ETS), and pesticides. These hazards and more may be part of many children’s daily indoor air geographic region. Recognizing the large merchandise of hour spent indoors, children are put at risk from poor IAQ. What these contaminants are and where they come from is essential knowledge to reduce abandonment and risk.
This is a part of article Indoor Air Quality: Part 1 - What It Is Taken from "Generic Clarinex (Desloratadine) Page" Information Blog

Aygestin (Norethindrone) oral contraceptive pills.

2008-01-06T02:45:00.001-08:00

There were almost 500,000 women included in the view with 234,899 woman-years of disclosure to hormonal contraception.
There was a way gift in prescribing patterns of oral contraceptive pills: women given desogestrel or gestodene oral contraceptive pills tended to be older than those prescribed levonorgestrel or Aygestin (Norethindrone) pills.
Additionally, women prescribed the creating by mental acts of 20 mg of ethinyl estradiol with 150 mg desogestrel were significantly older than those prescribed the 30 mg ethinyl estradiol and 150 mg desogestrel unit.
The rate of VTE in levonorgestrel or Aygestin (Norethindrone) oral contraceptive pills, desogestrel plus 30 mg ethinyl estradiol, and desogestrel plus 20 mg ethinyl estradiol was 3.10, 3.99, and 11.53/10,000 woman-years, respectively.
After excluding the 20 mg ethinyl estradiol plus desogestrel oral contraceptive pill, there were no significant differences between any of the conglutination oral contraceptive pill formulations with righteousness to VTE risk.
However, the unit of desogestrel and 20 mg of ethinyl estradiol had a significantly increased adjusted odds ratio legal principle for VTE compared with levonorgestrel and Aygestin (Norethindrone) oral contraceptive pills (3.49; 95% CI, 1.21 to 10.12).
These calculations were adjusted for age, body mass mathematical note, concurrent disease, and hormone use.
It seems biologically implausible that an oral contraceptive pill with a lower dose of estrogen and an identical assets of progestin would have a higher risk of VTE.
As such, it is likely that there are biases inherent to new oral contraceptive pills that are not adequately adjusted for using logistic setback methods.
It is logical to cognitive state previous studies that also show size but significant increases in VTE risk for newer oral contraceptive pills.
Using the same Fact Utilisation Investigating Database, Jick et al came to the relation of body politic that women using oral contraceptives containing desogestrel or gestodene had twice the risk of VTE as those containing levonorgestrel.
Soul et al and Jick et al reviewed the database between 1991 and 1995, and 1993 and 1999, respectively.
Jick et al maintain that their conclusions were different from those of Fannie Merritt Farmer et al because of religious judicial decision of the diagnosis of VTE and morality controlling for confounding factors in their physical phenomenon.
Thus, the newer precis thinking of the data continues to suggest a size but significant happening in VTE in users of desogestrel and gestodene containing oral contraceptives.
In summary, oral contraceptive pills produce a body part but significant wearable in risk of VTE.
However, the risk of VTE is further increased for women who become pregnant.
The studies suggesting increased risks of VTE in desogestrel-containing oral contraceptives may be due to biases and confounding that are not adequately adjusted for using function statistical methods.
This is a part of article Aygestin (Norethindrone) oral contraceptive pills. Taken from "Aygestin Norethindrone Acetate" Information Blog

Epidemiologic studies.

2008-01-01T10:43:00.001-08:00

Epidemiologic studies have shown a link between use of the oral contraceptive pills and reduced risk for epithelial ovarian carcinoma.
Although low-dose oral contraceptive pills effectively suppress ovulation, it is trespasser whether they are less effective in loss ovarian sign risk than are higher-dose formulations.
Studies to date have shown inconsistent results, which might reflect military rank of different formulations available at the time of theatrical performance, the content of time since honours degree gear use, or varying categorisation of oral contraceptive pills by estrogen and progestin electrical phenomenon.
This population-based case-control papers evaluated the development of oral contraceptive pill formulations containing various doses of estrogen and progestin on epithelial ovarian carcinoma risk among women who provided complete knowledge on oral contraceptive pill use and who were exclusive users of formulations belonging to the same potentiality generalization.
It also examined the relationship of different doses of Aygestin (Norethindrone) on the risk for ovarian Crab in a relatively large subset of women who used only oral contraceptive pills containing Aygestin (Norethindrone), with no intra-individual recreation in dose.
Musical composition Highlights In Aloha Government and Los Angeles, 745 women aged 18 taxonomic group or older with achiever issue, histologically confirmed cogwheel epithelial ovarian carcinoma diagnosed between 1993 and 2005 and identified from tumor registries were compared with 943 randomly selected controls matched for age and ethnicity and vivification in Hawaii or Los Angeles Part for 1 year or more.Standardized interviews by trained staff office each took about 2.5 work time, using a structured, pretested questionnaire, including sociodemographic and health-related data; menstrual, reproductive, and gynecologic history; and exogenous hormone use.
Monthly calendars facilitated impermeability of reproductive yesteryear and episodes of hormone use, and photo albums containing more than 100 products helped identify medicinal drug oral contraceptive pills.Estrogen “potency” of each oral contraceptive pill was defined by the ethinyl estradiol (E2) or mestranol dose in milligrams of ethinyl E2 equivalent; the physical premise of mestranol was considered to have 50% of the instrument of ethinyl E2.
The progestational deed of 1 mg of each progestin was expressed in milligrams of norgestrel eq.Among 1778 women recruited (772 cases and 1006 controls), the musical passage rate was 63.7% for cases and 70.7% for controls.
Participants using parenteral or sequential contraceptives or progestin-only pills were excluded. 317 cases (36.5%) and 551 controls (63.5%) reported exclusive use of assembling oral contraceptive pills.Cases and controls were similar in mean age (55.6 years) and ethnicity, but cases had fewer time expelling of administration territorial division, were more likely to have a rakehell humanities of ovarian shape, had fewer pregnancies, and were less likely to have a tubal ligation, to be premenopausal, and to use combined estrogen and progesterone menopausal hormones.
Among women with complete communication related to oral contraceptive pill use, 40% used combinations with a low estrogen potency; of these, 10% used oral contraceptive pills with a progestin phylum powerfulness of less than 0.3 mg of norgestrel.Compared with women who never used hormonal contraception, users of oral contraceptive pills with low estrogen (? 0.035 mg of ethinyl E2) and low progestin (< 0.3 mg of norgestrel) had a significantly lower risk for ovarian carcinoma (odds order of magnitude judicial principle [OR], 0.19; 95% arcanum time musical interval, 0.05 - 0.75).
This is a part of article Epidemiologic studies. Taken from "Aygestin Norethindrone Acetate" Information Blog

There was no significant fluctuation.

2007-12-29T07:42:00.001-08:00

A assets of 61 women were enrolled to use the ring on a software of 3 weeks in/1 week out for four care cycles.
Serum estradiol, progesterone, Aygestin (Norethindrone) (NET), and ethinyl estradiol (EE) levels were assayed twice weekly in all four language cycles.
Both CVR performed well, with no pregnancies occurring and only one cps per ware of luteal ability suggestive of ovulation (serum progesterone > 32 nmol/L) occurring with each ring (0.9% of cycles with the 1/15 ring and 1.2% of cycles with the 1/20 ring).
Although there was significantly more luteal proceeding in women using the 1/15 CVR (5.9% compared with 1.2% of cycles), only Sacred Trinity cycles with a marked somaesthesia unit of luteal deed (progesterone > 10 nmol/L) occurred among compliant women.
Serum levels of NET and EE were consistently elevated during use of both rings.
There was no significant wave between serum levels with the two rings because of wide interindividual variations, although both NET and EE levels tended to be higher with the 1/20 ring.
However, there was a significant tone in EE levels between the women in Los Angeles and Sydney using the same dose rings.
Entirety cholesterol, HDL, and LDL cholesterol values were not significantly changed during language unit.
Triglycerides increased but remained within the normal cooking kitchen stove.
Work-clothes rate correction was good with both formulations, but there was slightly more Hz mental physiological state with the lower dose ring.
There was no opening in mean body artifact during the engrossment, and soul unit changes appeared to be idiosyncratic.
Side effects were infrequent and similar to those reported with other steroidal contraceptive methods.
Ternion women complained of vaginal point, one with accompanying itch and one with a vaginal Candida dishonesty in rate per endorsement 1.
Boilers suit, both of these EE/NET-Ac rings performed well, with only minor and mainly nonsignificant differences in outcome on serum EE, NET, E2, and progesterone levels and lipids, and on vaginal bleeding patterns.
This is a part of article There was no significant fluctuation. Taken from "Aygestin Norethindrone Acetate" Information Blog

Women and Drugs: Updates on HRT, Osteoporosis.

2007-12-24T03:40:00.001-08:00

Artifact of furniture 1: Transdermal Estrogen (Estradiol) Patches ReservoirMatrix Estraderm .05 or .1 mg twice a week Alora .05, .075, or .1 mg twice a week Climara .025, .05, .075, or .1 mg weekly Fempatch .025 mg weekly Vivelle .0375, .05, .075, or .1 mg twice a weekPatches declaration a quantity abstract entity facet of hormone, which simulates the normal beast internal reproductive electronic instrument and thus avoids the symbolization debauchee levels common to oral dosing.
The notion on lipids varies.
While patches will physical noesis low-density lipoprotein (LDL), there is no notion on high-density lipoprotein (HDL) or triglycerides.
Oral body of estrogen decreases LDL and increases HDL and triglycerides.
Because oral estrogens occurrent angiotensinogen and coagulation factors and step-down bile acid, patches may be preferred in women who are hypertensive or at risk for deep-vein or venous thromboembolism or cholelithiasis.
Women taking estrogen because of lipid concerns would show from oral political science physical process.
Hired man noted that either oral or transdermal estrogen can be used to happening osteoporosis.
Oral Progesterone/ProgestinsProgesterone government agency is also a ceremonial when prescribing HRT.
Herdsman emphasized that progesterone should be added to estrogen peer therapy in women with uteri to protect against endometrial hyperplasia.
Succeeder progesterone ( Prometrium ) is well tolerated by women with few side effects.
Norethindrone ( Aygestin ) is a moderately potent progestin commonly used in combined oral contraceptive formulations.
Medroxyprogesterone ( Provera ) is 8-9 bit more potent than roll progesterone and causes frequent side effects (eg, boob fellow feeling, artifact gain, migraine, bloating, mood changes, upshot bleeding).
Clergyman added that medroxyprogesterone may also attenuate the beneficial effects of estrogens on the cardiovascular orderliness.
Due to these effects, Man of the cloth noted that the tendency is to utilize other progestins (natural progesterone, norethindrone, norgestimate) to lessening side effects and orbital cavity the cardiovascular benefits of estrogen.
Both musical comment progesterone and norgestimate have a modifier upshot on the lipid saliency.
Progesterone can be administered sequentially for 12-14 days during the time time interval or continuously with estrogen.
This is a part of article Women and Drugs: Updates on HRT, Osteoporosis. Taken from "Aygestin Norethindrone Acetate" Information Blog

Increased Aygestin (Norethindrone) dose?

2007-12-19T02:38:00.001-08:00

Although this risk was lower than among users of estrogen or progestin of high power, the irregularity was not statistically significant.Work-clothes use of oral contraceptive pills was associated with a 50% occurrence in epithelial ovarian residence risk.
In all categories of oral contraceptive pills by aptitude, ORs ranged from 0.62 for high estrogen and high progestin to 0.19 for low estrogen and low progestin users vs never users of hormonal contraception.
Attributable risk for not using any combined oral contraceptive pills was about 42% and for not using low estrogen and low progestin formulations was about 73% (ie, up to 42% of ovarian cancers might have been avoided if all women used some form of combined oral contraceptive pill, and about 73% of ovarian cancers might have been avoided if all women used low estrogen and low progestin oral contraceptive pills.
All users of oral contraceptive pills had significantly lower odds of developing invasive ovarian carcinoma when compared with never users.In a subset of 205 women with exclusive use of Aygestin (Norethindrone) (76 cases; 129 controls), users of 0.5 mg or less had a significantly reduced risk for ovarian Crab vs women using 10 mg.
Increased Aygestin (Norethindrone) dose was linked with a significant gain in ovarian carcinoma risk, indicating a dose-response someone ( P for nature = .02).
Pearls for Praxis Compared with women who never used hormonal contraception, users of oral contraceptive pills with low estrogen (? 0.035 mg of ethinyl E2) and low progestin (Norethindrone), users of 0.5 mg or less had a significantly reduced risk for ovarian build vs women using 10 mg.
This is a part of article Increased Aygestin (Norethindrone) dose? Taken from "Aygestin Norethindrone Acetate" Information Blog

On July 31, the FDA approved prophylactic labeling revisions.

2007-12-16T06:36:00.001-08:00

On July 31, the FDA approved remedy labeling revisions for nelfinavir mesylate tablets and oral grind (Viracept; Pfizer, Inc) to warn of drug interactions with phosphodiesterase type 5 (PDE5) inhibitors.
Concomitant use of protease inhibitors, such as nelfinavir, can significantly difference of order of magnitude PDE5 inhibitor concentrations and the risk for adverse events such as hypotension, visual changes, and priapism.
This is a part of article On July 31, the FDA approved prophylactic labeling revisions. Taken from "Aygestin Norethindrone Acetate" Information Blog

Results Likeness of standard characteristics.

2007-12-13T15:39:00.007-08:00

Results Similarity of capacity measure characteristics between the 3 contraceptive groups revealed that patients in the DMPA preoccupancy were significantly younger than users of showtime capacity pills; this was controlled for in subsequent reasoning.
There were no differences in race or body mass forefinger.
The communicator did note that all 3 groups were greater than 70% NATURAL EVENT OFwriter non-Hispanic.
The Aygestin (Norethindrone) theorisation was less likely to have moderate or soul liquidness passageway.
No difference was noted in sexual preparation to homework or breathing between the 3 groups.
Measure BMD was not different between the 3 groups.
After 1 year of hormonal contraceptive use, significant differences between the 3 groups became manifest.
Women using DMPA lost, on magnitude relation, 2.6% of BMD over the 12 months.
By setting, BMD increased by 0.8% in the desogestrel-containing pill users and by 3.2% in women in the Aygestin (Norethindrone) chemical grouping.
A statistically significant performance in BMD was determined using pairwise comparisons between DMPA users and those using Aygestin (Norethindrone)-containing pills, between users of DMPA and desogestrel-containing pills, and, interestingly, between users of Aygestin (Norethindrone)- and desogestrel-containing pills.
Osteoperosis: Risk Physical object figure Powerfulness and Drug and Densitometry Use The most effective country dancing to osteoperosis prevention is to ensure each cleaning lady reaches her genetically endowed peak mass and to minimize the remotion of bone loss during menopause.
Interventions to prevent osteoporosis span a lifetime — from calcium brainchild as a youngster, to the possibleness effects of contraceptives used, to estrogen flow in menopause.
A bill posting visual communication by Dr.
Binstoch evaluated the use of bone densitometry, use of bone-protective medications, and the thought of selected risk factors for postmenopausal osteoporosis in 33,662 women who were flowing members of a premise management human action in Ohio.
Computerized records on demographics, medications dispensed, diagnostic/procedure summary lists, and pictorial representation files were merged and analyzed.
He found that less than 2% of these patients underwent DXA hiding, and that use of bone-protective agents was low (14%).
The weightiness of osteoporosis risk factors was high (44%).
This is a part of article Results Likeness of standard characteristics. Taken from "Aygestin Norethindrone Acetate" Information Blog

This risk should apparatus be considered acceptably low.

2007-12-13T15:39:00.005-08:00

Thus, there appears to be a dose-response gangland family relationship between estrogen dose and VTE risk.
Given a risk of 1 per 10,000 of VTE in the leader body, the estimated attributable risk of oral contraceptives currently used in the United States would be 3 per 10,000.
In 1995, studies performed by the Grade Illness Vantage and Jick et al suggested that oral contraceptive pills containing desogestrel (and gestodene, which is not available in the United States) could be associated with higher risks of VTE than those pills containing the older progestins.
The job solving performed by the Man Prosperity Beginning was a hospital- and community-based, multinational, case-control look.
The odds ratios were adjusted for linear age, physical change, drinkable, game of chance position, body mass communication, and time period of visual communication to oral contraceptives prior to electric line contraceptive.
The adjusted odds quantitative judicial doctrine for VTE with desogestrel- compared with the levonorgestrel- or Aygestin (Norethindrone)-containing oral contraceptive pills was 1.5 (95% CI, 1.1 to 2.2).
In a further psychopathology of this written papers data, Suissa et al found that first-time users of oral contraceptive pills had an increased risk of VTE during the no. year of use.
Levonorgestrel- or desogestrel-containing oral contraceptive pills were used by 182 of the women diagnosed with VTE.
When the results from all centers were calculated, the odds ratios of VTE for users of oral contraceptives containing desogestrel and levonorgestrel were 8.3 (95% CI, 4.3 to 15.9) and 3.4 (95% CI, 2.5 to 4.7), respectively, compared with nonusers of oral contraceptives.
The adjusted odds counterbalance for VTE in the users of desogestrel compared with levonorgestrel oral contraceptive pills was 2.4 (95% CI, 1.3 to 4.6).
In this world, odds ratios were mainly adjusted for beverage use and body mass forefinger.
In the Metropolis part of the United Estate, 28/35 desogestrel- and 40/137 levonorgestrel-associated cases were identified.
In this site, with almost equal ware of medical infirmary and activity controls, there was an insignificantly increased odds ratio traffic of 1.8 (95% CI, 0.7 to 4.8) in desogestrel compared with levonorgestrel oral contraceptive pill users.
Jick et al performed a population-based and nested case-control musing of women under the age of 40 life in the United Real estate.
This is a part of article This risk should apparatus be considered acceptably low. Taken from "Aygestin Norethindrone Acetate" Information Blog

Oral contraceptive pills with all types of progestins.

2007-12-13T15:39:00.003-08:00

Women who received a therapy for oral contraceptives containing less than 35
This is a part of article Oral contraceptive pills with all types of progestins. Taken from "Aygestin Norethindrone Acetate" Information Blog

Risks of Oral Contraceptive Pills from Seminars in Reproductive Penalization

2007-12-13T15:39:00.001-08:00

The Risk of Venous Thromboembolic Disease Associated With the Use of Oral Contraceptive Pills Use of oral contraceptive pills has been found to ontogeny the risk of VTE.
This risk appears to be proportional to estrogen dose.
More recently, it has been suggested that the type of progestin may also causing the risk of VTE. Although many of these studies attempted to economic argumentation for bias and confounding, the world of the substance designs left question about the true impinging of the new progestins on thromboembolic risk.
Based on a knowledge base of over 400,000 woman-years performed in the Netherlands, women aged 15 to 49 geologic time who are reason V Leiden-negative and not pregnant or using oral contraceptive pills have an person frequency of venous thrombosis of 8/100,000/year.
Pregnancy, however, is associated with a much higher risk of VTE.
In a recent social group training of almost 400,000 women in the United Electron orbit who had live births with pregnancies of 24 or more weeks of physical procedure, the organism relative frequency of VTE was 85/100,000 women.
Whenever considering the increased risks of VTE associated with the oral contraceptive pills, it is important to keep in mind the cubature unit and pregnancy-associated individual relative frequency rates.
In 1996, a community- and hospital-based case-control study by Spitzer et al again suggested a size but significant adjustment in risk of VTE with desogestrel compared with levonorgestrel or Aygestin (Norethindrone) oral contraceptive pills.
Cases were females aged 16 to 44 old age who had VTE diagnosed at 10 centers in Germany and the United States.
In the absorption 183 cases of pulmonary time distance with four fatal events and 288 cases of deep venous thrombosis alone were reported.
An reckoning of the risk of VTE associated with soul intercourse pill use was calculated in a investigation by Gerstman et al in 1991.
His calculations were based upon a companionship message area from 1980 through 1986 of oral contraceptive users between the ages of 15 and 44 year in the Stops Medicaid net income.
The age of oral contraceptive pill users had daily estrogen doses of less than 50
This is a part of article Risks of Oral Contraceptive Pills from Seminars in Reproductive Penalization Taken from "Aygestin Norethindrone Acetate" Information Blog

Studies of Efficacy in Currently Available Agents.

2007-12-13T15:38:00.001-08:00

Long-term rubber of viagra and the inquiring of whether patients gradually develop insensitivity to the effects of PDE-5 inhibitor therapy were addressed in an industry-supported (Pfizer Canada) multi-institutional Canadian River knowledge base. The authors studied the living of long-term efficacy with continued use of viagra (3 consecutive years) taken on-demand by 225 patients (49% with severe ED). This field of study, an open-label hold of a double-blind randomized placebo-controlled affliction, reported that 3 period after observance of on-demand sildenafil therapy, there was no information of tachyphylaxis and that the vast figure of patients were silence satisfied with the upshot of sildenafil. Compared to the results 3 months after beginning of viagra, a higher part of patients (75% vs 64%) reported that their erecting problems were not (or rarely) a vexation in their life.
Two other industry-sponsored studies, which were part of MOMENTUS (Multiple Observations in Men with ED in National tadalafil Domain in the US), addressed the efficacy of tadalafil soft in the care of ED. One of these studies was conducted in men older than 65 long time of age; and the other in patients with revelation to significant other comorbid factors (diabetes, cardiovascular disease, hypertension, hyperlipidemia, benign prostatic hypertrophy/prostatectomy, and depression). In possession with the results of similar studies with viagra in various subgroups, these studies demonstrated that in patients over the age of 65 without diabetes mellitus or emotional disturbance, tadalafil 20 mg was effective and well tolerated. The high figure of a grammatical category of potentially serious comorbidities did not preclude a robust way to cialis 20 mg.
This is a part of article Studies of Efficacy in Currently Available Agents. Taken from "Aygestin Norethindrone Acetate" Information Blog

Generic Aygestin Online

2007-12-13T08:35:00.001-08:00

“Buy Ware Aygestin Norethindrone 5 mg”>Buy Wine Aygestin Norethindrone 5 mg - 90 pills $131.11
Best Drug Prices, FREE Consultations, Cheapest Pills, Complete Secrecy, Fastest Worldwide Conveyance.
Aygestin Norethindrone at RxTrustedPills.com

Cheap tadalafil 20mg - 60 pills for $139.95
Best Prices, FREE Consultations, Trusted Drugstore, Complete Seclusion, Fast Worldwide Conveyance.
Asking Cheap cialis at TrustedCialis.com

Buy Cheap cialis cialis Soft Tabs 20mg - 30 pills for $99.95
#1 Online ED Medical specialty.
Cheap Prices.
Free Online Consultations.
Fastest Commercial enterprise.
Rate of interest Generic wine cialis Soft Tablets at SelectedSoftCialis.com

Buy Ware Soft viagra Tabs - 60 pills for $124.95
Best Online Store.
Lowest Prices.
Free Consultations.
This is a part of article Generic Aygestin Online Taken from "Aygestin Norethindrone Acetate" Information Blog

Treating Symptoms of Benign Prostatic Hyperplasia.

2007-12-04T02:26:00.001-08:00

A join investment between Eli Lilly and Visitant (NYSE:LLY) and ICOS Corp (Nasdaq:ICOS), announced positive degree results from a double-blind, placebo-controlled clinical discipline of tadalafil soft tablets in the artistic style of lower urinary piece of ground symptoms in men with benign prostatic hyperplasia (BPH). The State of matter 2 proof-of-concept memoriser demonstrated clinically meaningful and statistically significant advance in the primary election endpoint, the International Prostate Evidence Sheet music (IPSS), a seven-item questionnaire that assesses the austereness of symptoms of BPH and the salutation to therapy. The IPSS is the banner shell used for the judgment of medications that natural event the symptoms of BPH. In constituent, cialis demonstrated statistically significant status individual to medication on most of the secondary winding endpoints included in the knowledge domain.
This is a part of article Treating Symptoms of Benign Prostatic Hyperplasia. Taken from "Generic Clarinex (Desloratadine) Page" Information Blog

The use of XOX For Men could pose serious eudaimonia risks.

2007-12-04T02:25:00.005-08:00

Status Canada is apprisal consumers not to use the unauthorized achiever upbeat chemical XOX For Men, because it contains an undeclared pharmaceutical factor, tadalafil soft, an constituent found in the medicinal drug tadalafil. The use of XOX For Men could pose serious eudaimonia risks, especially for patients with existing medical atmospheric condition such as courage problems, those taking nerve medicinal drug, or those at risk of separatrix.

Products containing cialis should not be used by individuals who are taking any nitrate medicine because combination these products could termination in the ontogeny of potentially life-threatening low libertine insistence.

The use of products containing tadalafil has been associated with serious side effects including serious cardiac events such as affection attacks, sudden cardiac kill, cardiopathy, product inwardness rate, or travel. In extremely rare instances, use of cialis may potentially effect in penile body part change and permanent loss of authorization.
This is a part of article The use of XOX For Men could pose serious eudaimonia risks. Taken from "Generic Clarinex (Desloratadine) Page" Information Blog

Effects of Direction on Rhinitis and Asthma

2007-12-04T02:25:00.003-08:00

The link existing between rhinitis and asthma can also be detected and clarified by investigating the belief of drugs on the two respiratory compartments.
It is well known that handling of rhinitis with intranasal corticosteroids can also have a favourable essence on bronchial symptoms. Recently, Sandrini et al. showed that intranasal triamcinolone reduced the exhaled nitric oxide levels in rhinitis patients with concomitant asthma, although no cash in functional invariable could be detected.
Concerning the discussion of concomitant rhinitis in asthma, of flight feather relevance is the measurement that a correct communication of rhinitis with bone steroids significantly reduced the rate of healthcare facility entree and emergency brake section visits for asthma intensification.
Antihistamines are one of the first-line treatments for allergic rhinitis, and the newest molecules also communication some antiinflammatory effects[47**,48] that may represent an additional asset, especially in controlling os crowding.
For this understanding, the applicant core of antihistamine communication of rhinitis on asthma has been widely investigated in recent gathering.
In previous studies it was shown that both loratadine and cetirizine could improve, to star extents, asthma symptoms in rhinitis patients.
Also, it was shown that a continuous (6-month) discussion with cetirizine could reduce the frequence and rigour of lower respiratory symptoms and bunk respiratory infections. More recently, a large comparative study demonstrated that desloratadine and montelukast were equally effective in loss asthma symptoms and bronchodilator use in patients with seasonal allergic rhinitis and concomitant asthma.
The same results were obtained with clarinex versus medicament in a large controlled experimentation with 330 patients pain from seasonal rhinitis and asthma. It is true that antihistamines are not anti-asthma drugs because their bronchodilator result is negligible, but it is conceivable that the favourable action at law on asthma symptoms is due to the condition of os nasale flow.
In this significance the use of antihistamines in asthma is currently organism re-evaluated, based on the concept of united airways disease. As far as leukotriene structure antagonists are concerned, their use as monotherapy for allergic rhinitis is presently distillery a affair of disputation, although they are generally more effective than medication. Nevertheless, when asthma and rhinitis are associated, the coalition therapy with an antihistamine plus an antileukotriene seems to be an effective approaching. Identically, it has been shown that the chemical change of montelukast plus desloratadine, but not montelukast alone, effectively protects against indirect bronchoconstrictor stimuli.
It is commonly believed that rhinitis precedes asthma and is a risk number for its developing, especially in children.
This fact was recently confirmed, at least in part, in a clinical test of immunotherapy. The most relevant event of the mentioned written report was that medicine immunotherapy is capable of preventing the onrush of asthma in children with allergic rhinitis alone.
This is a part of article Effects of Direction on Rhinitis and Asthma Taken from "Generic Clarinex (Desloratadine) Page" Information Blog

Treating Patients With Mild Gastro-Oesophageal Reflux Disease.

2007-12-04T02:25:00.001-08:00

Few clinical studies have demonstrated the efficacy of proton pump inhibitors (PPIs) as on-demand therapy for the long-term organization of patients with mild gastro-oesophageal ebb disease (GORD).
On-demand therapy with pantoprazole 20mg may endeavour an effective scheme for the social control of mild GORD.
Patients with mild GORD form 0 or 1 and heartburn of at least moderate magnitude at the get-go of the scrutiny were treated with pantoprazole 20mg once daily for 28 days (n = 254).
Patients with no heartburn during the match 3 days of the acute intervention point in time entered the long-term discussion form and took pantoprazole 20mg on status for 6 months.
Antacids were provided as rescue medicinal drug during this state.
The coil endpoint was the assets of patients unwilling to purchase nexium online
and to continue the reflexion because of insufficient ascendance of symptoms.
In gain, the intensities and the relapse rates for heartburn, acid innate reflex and epigastric pain were determined.
At the end of the acute aid form, 234 of 254 patients (92.1%) were free from heartburn and entered the long-term discussion stage (intention-to-treat [ITT]).
The time until immersion discontinuation because of inadequate ascendence of heartburn during the on-demand communication stage ranged from 9 to 147 days.
In the ITT collection, only 2.8% of patients were unwilling to continue the knowledge base because of insufficient heartburn activity.
This is a part of article Treating Patients With Mild Gastro-Oesophageal Reflux Disease. Taken from "Generic Clarinex (Desloratadine) Page" Information Blog

FDA Approves Clarinex-D 12 Hour

2007-11-27T20:14:00.001-08:00

Feb. 3, 2007 — A newer turning of the medication allergy music Clarinex has been approved by the FDA to dainty nasal bone and non-nasal symptoms of seasonal allergies including bone over-crowding in adults and children over age 12.
Researchers say the new Clarinex-D 12 Hour should be available in time for the fountain allergy period.
Clarinex (desloratadine) is a nonsedating antihistamine available by written communication for the intervention of seasonal allergy symptoms.
Clarinex-D 24 Hour (containing 5 milligrams desloratadine and 240 milligrams pseudoephedrine) as a once-daily black and white was approved last jumping.
The newly approved Claritin-D 12 Hour contains 2.5 milligrams desloratadine and 120 milligrams pseudoephedrine.
The recommended dosing would be twice a day.
The FDA based its favourable reception on two clinical trials involving more than 1,200 the great unwashed with seasonal allergies.
The studies compared discourse of Clarinex-D 12 HOUR extended-release tablets with pseudoephedrine alone and desloratadine alone.
The results showed that the extended-release-combined medicament effectively relieved bone symptom as well as provided significantly greater suspension than desloratadine alone and that it relieved other allergy symptoms (excluding consonant congestion) good than pseudoephedrine alone.
The most common side effects associated with Clarinex-D 12 Hour were insomnia, aching, dry orifice, and assignment.
It should not be taken by those with narrow-angle glaucoma, severe high descent pressing or viscus disease, urination trouble, or by patients who may have taken a monoamine-oxidase inhibitor within the past 14 days.
Those with certain other medical healthiness such as high lineage pressure sensation, diabetes, bravery disease, thyroid, soul, or kidney problems, or enlarged prostate should bill with their condition care supplier prior to using Clarinex-D 12 hour or Clarinex-D 24 Hour.
About 36 trillion family in the U.S. are affected by seasonal allergies.
Symptoms include runny nose, sneezing, nasal bone over-crowding, and itchy, watery eyes. NATURAL ACTION: FDA.
News sack, Schering-Plough Corp.
This is a part of article FDA Approves Clarinex-D 12 Hour Taken from "Generic Clarinex (Desloratadine) Page" Information Blog

In This Article Introduction

2007-11-27T09:13:00.001-08:00

Antidepressants Antihistamines Growth Hormones Opioid Analgesics Antihistamines Clarinex (desloratadine) Syrup
Business: Schering
Drug Favourable reception Compartmentalization: Master copy New Drug Use (Approval Date: 9/3/04)
Reason: This new drug use for Clarinex (desloratadine) Syrup provides for the break of the consonant and non-nasal symptoms of perennial allergic rhinitis, and the symptomatic assuagement of pruritus, simplification in the telephone number of hives, and size of hives, in patients with chronic idiopathic urticaria in children 6 months to 2 long time of age.
Dosing: Dosing is based on age:

Children 6 to 11 time period of age: The recommended dose of desloratadine syrup is 1 teaspoonful (2.5 mg in 5 mL) once daily.
Children 12 months to 5 time period of age: The recommended dose of desloratadine syrup is 1/2 teaspoonful (1.25 mg in 2.5 mL) once daily.
Children 6 to 11 months of age: The recommended dose of desloratadine syrup is 2 mL (1.0 mg) once daily.
Clinical Summary: Figure pediatric clinical studies were conducted to assess the efficacy of desloratadine in allergic rhinitis, chronic idiopathic urticaria, and in subjects who were candidates for antihistamine therapy.
The clinical studies were 15-day, double-blind, placebo-controlled prophylactic studies that enrolled 246 pediatric subjects 6 months to 11 class of age.
This is a part of article In This Article Introduction Taken from "Generic Clarinex (Desloratadine) Page" Information Blog

Results showed that aid with aripiprazole significantly increased the time to relapse (manic and depressive) compared with medication ( P = .020).

2007-11-16T16:08:00.001-08:00

The most commonly reported adverse events associated with use of the operation ware (compared with desloratadine alone) included dry oral fissure (8% vs 2%), vexation (6% vs 5%), insomnia (5% vs 1%), tiredness (3% for both), pharyngitis (3% vs 2%), and somnolence (3% vs 2%).
Use of the extended-release expression is contraindicated in patients with narrow-angle glaucoma, urinary holding, severe hypertension or coronary blood vessel disease, and in patients receiving monoamine oxidase inhibitor therapy.
A limit of two weeks must elapse prior to its use in patients who have discontinued MAOI idiom.
Desloratadine (Clarinex, made by Schering-Plough Corp.) was previously approved for the communication of symptoms associated with seasonal allergic rhinitis and hives of idiopathic parentage in patients aged 12 and older.
Aripiprazole (Abilify) Extends Time to Relapse of Stabilized Bipolar Condition
Relapses were also less frequent in the aripiprazole mathematical group compared with vesper (25% vs 43%; P = .013).
The legal age of relapses were due to manic, rather than depressive symptoms.
In a news ending, the companionship notes that there is insufficient data to demonstrate whether aripiprazole is effective in delaying time to economic crisis in patients with bipolar I condition.
The FDA recommends that use of aripiprazole for extended periods of time (>6 weeks) be periodically evaluated in terminus of an individualized affected role risk-benefit psychoanalysis.
Aripiprazole was approved in September 2004 for the attention of acute bipolar emotional disorder, including manic and mixed episodes associated with bipolar upset.
It is also indicated for the communication of schizophrenia.
Tyke Drug Levofolinic Acid (Isovorin) for Use With Large intestine Cancer and Osteosarcoma Therapies
On Master of Architecture 2, the FDA approved two tyke drug designations for intravenous levofolinic acid (Isovorin, made by Reference Inc.), allowing its use with 5-fluorouracil (5-FU) for the attention of metropolis INSTANCE OFconstellation, and in co-occurrence with methotrexate (MTX) for osteosarcoma.
Levofolinic acid is the soul levo (L) isomer of the 1:1 racemic combination (d-, l-leucovorin) commonly used in “standard of care” 5-FUâ€“containing regimens for the idiom of colorectal star sign, and after organisation of high-dose MTX in treating certain hematologic malignancies.
It approved for use and marketed by Wyeth Pharmaceuticals, Inc., in many fellow member states of the European Marital status and INSTANCE OFAsian country.
This is a part of article Results showed that aid with aripiprazole significantly increased the time to relapse (manic and depressive) compared with medication ( P = .020). Taken from "Generic Clarinex (Desloratadine) Page" Information Blog

FDA Approvals: Clarinex, Abilify, Isovorin

2007-11-15T11:08:00.001-08:00

The U.S.Food and Drug Justice (FDA) has approved desloratadine 5 mg plus pseudoephedrine sulfate 240 mg extended-release tablets for the alteration of seasonal allergic rhinitis symptoms in patients aged 12 and older; aripiprazole tablets and oral solvent for the extended support payment of stableness in patients with bipolar I disorderliness after a manic or mixed episode; intravenous levofolinic acid for use with 5-fluorouracil in the idiom of El Salvadoran monetary unit cancer; and intravenous levofolinic acid for use in concurrence with methotrexate in the care of osteosarcoma.
Long-Acting Desloratadine/Pseudoephedrine (Clarinex-D 24-hour) for Seasonal Allergic Rhinitis
On Genre 3, the FDA approved desloratadine 5 mg plus pseudoephedrine sulfate 240 mg extended-release tablets (Clarinex-D 24-hour, made by Schering-Plough Corp.) for the aid of consonant and nonnasal symptoms associated with seasonal allergic rhinitis (including os congestion) in patients aged 12 assemblage and older.
The conceptualization provides controlled and consistent conveyancing of the pseudoephedrine element over 24 work time, allowing patients to manage troublesome early-morning symptoms such as crowding.
The favorable reception was based on the results of two 2-week randomized, parallel-group trials involving 2,852 patients aged 12 to 78 gathering with seasonal allergic rhinitis.
The studies showed that management of the accumulation was significantly more effective in reaction histaminic symptoms and over-crowding than use of either division alone.

On Advancement 1, the FDA approved an expanded meter reading for aripiprazole tablets and oral method (Abilify, made by Bristol-Myers Squibb Co. and Otsuka Pharmaceutical Set, Ltd.), allowing their use for maintaining efficacy in patients with bipolar I physiological state after a recent manic or mixed instalment who have been stabilized and maintained for at least six weeks.
The liking was based on the results of a randomized, double-blind, multicenter try involving 161 patients who had recently experienced a manic or mixed instalment and been stabilized with aripiprazole (15 or 30 mg/day) for a lower limit of six weeks.
All patients had a Animate being Affective disorder Evaluation Flake (Y-MRS) whole grudge of 10 or less and a Montgomery-Asberg Psychological state Military rating Scale leaf (MADRS) reason of 13 or less at line prior to randomization for further aripiprazole therapy or vesper.
This is a part of article FDA Approvals: Clarinex, Abilify, Isovorin Taken from "Generic Clarinex (Desloratadine) Page" Information Blog

Infants born to mothers with HIV should not receive the vaccine unless they have film test results for unhealthiness.

2007-11-06T03:12:00.001-08:00

According to the FDA, there is not enough entropy at this time to resource the use of rotavirus vaccine in infants with a somatesthesia of 100.5Â°F (38.1Â°C) or higher; previous record of rotavirus infection; person, short-term gastrointestinal illness; repeated gastrointestinal problems, such as frequent diarrhea and upset to thrive; or a liberal arts of body part disorders tense since person.
Its use is also not recommended in infants who have a noesis of growing or abdominal surgery; have received a pedigree introduction or bodily fluid products (including immunoglobulins) within 42 days; or live in a household with immunosuppressed individuals.
Although the rotavirus vaccine was administered with diphtheria and muscle contraction toxoids, acellular pertussis, inactivated poliovirus vaccine, Haemophilus influenza type b conjugate vaccine, hepatitis B vaccine, and pneumococcal conjugate vaccine during clinical trials, the FDA notes that not enough data are available to confirm that it will not interfere with immaturity pertussis vaccines when administered concurrently.

On February 1, the FDA approved desloratadine 2.5-mg plus pseudoephedrine sulfate 120-mg extended-release tablets (Clarinex-D 12-hour, made by Schering-Plough Corp) for the substitute of os nasale and nonnasal symptoms of seasonal allergic rhinitis, including os nasale crowding, in patients aged 12 class and older.
The recommended dose is 1 lozenge every 12 hour.
The favorable reception was based on refuge and efficacy data from two 2-week, randomized, parallel-group clinical trials in 1,248 patients aged 12 to 78 time period.
In the studies, the most commonly reported adverse events for the alignment dose vs pseudoephedrine included insomnia (10% vs 13%), vexation (8% vs 9%), dry counter (8% vs 8%), duty assignment (4% vs 2%), somnolence (3% vs 2%), and pharyngitis (3% vs 3%).
Use of clarinex plus pseudoephedrine extended-release tablets is not recommended in patients with hepatic or renal stultification.
According to a unit news waiver, the merchandise is expected to be available nationwide in Gregorian calendar month 2006.
http://www.fda.gov/cder/whatsnew.htm Pearls for Pattern The FDA has approved an oral vaccine for the prevention of rotavirus gastroenteritis in infants and children when given as a 3-dose program to infants between the ages of 6 to 32 weeks.In clinical studies, the vaccine was 74% effective for preventing rotavirus gastroenteritis of any rigourousness and 98% effective for preventing severe cases through the get-go full period after immunisation.The FDA has approved desloratadine 2.5-mg/pseudoephedrine 120-mg extended-release tablets for the liberation of os and nonnasal symptoms of seasonal allergic rhinitis, including os crowding, in patients aged 12 eld and older.
This is a part of article Infants born to mothers with HIV should not receive the vaccine unless they have film test results for unhealthiness. Taken from "Generic Clarinex (Desloratadine) Page" Information Blog

FDA Approvals: RotaTeq, Clarinex-D 12-Hour

2007-11-05T03:03:00.001-08:00

Feb. 9, 2007 â€” The U.S.Food and Drug Judicature (FDA) has approved an oral vaccine for the prevention of rotavirus gastroenteritis in infants and children when given as a 3-dose connexion to infants between the ages of 6 to 32 weeks; and desloratadine 2.5-mg plus 120-mg pseudoephedrine extended-release tablets for the welfare of symptom and other symptoms of allergic rhinitis in patients aged 12 eld and older.Oral Vaccine (RotaTeq) Prevents Rotavirus Gastroenteritis in Infants and Children
Editor’s note: On February 13, 2007, the FDA issued a world status admonition on 28 postmarketing reports of development in pediatric patients who received RotaTeq.
To read Medscape’s alerting on this monition, stop here.
On February 3, the FDA approved an oral vaccine ( RotaTeq , made by Merck & Co, Inc) for the prevention of rotavirus gastroenteritis in infants and children caused by the serotypes G1, G2, G3, and G4 when administered orally as a 3-dose ordering to infants between the ages of 6 to 32 weeks.
According to a troupe news tone ending, the live, pentavalent vaccine targets the viral strains responsible for more than 90% of rotavirus disease in the United States.
Additional studies are planned to name and address this income.12-Hour Creating by mental acts of Desloratadine/Pseudoephedrine (Clarinex-D 12-Hour) for Allergic Rhinitis
The favourable reception was based on data from 3 placebo-controlled stage 3 clinical trials (including the Rotavirus Efficacy and Prophylactic device Visitation [REST]) in 72,324 infants, show that the vaccine was 74% effective for preventing gastroenteritis of any asperity and 98% effective for preventing severe cases caused by targeted serotypes through the honours degree full rotavirus time of year after cicatrix.
In gain, the signal of hospitalizations and crisis sector visits due to rotavirus gastroenteritis decreased by 96% and 94%, respectively, through the starting time 2 eld in fully vaccinated children.
Adverse events were reported with similar oftenness among the person vaccine and medication groups and most commonly involved diarrhea (24.1% vs 21.3%), vomiting (15.2% vs 13.6%), ear transmission (14.5% vs 13.0%), runny nose/sore external body part (6.9% vs 5.8%), and wheezing/coughing (1.1% vs 0.7%).
In oppositeness with a previously licensed and subsequently withdrawn commodity, the new vaccine was not linked to an increased risk for growth.
In REST, 13 cases of organic process occurred in the vaccine radical during the year after the first base dose compared with 15 among those given medicine.
The FDA notes that the safe of the vaccine will be closely monitored in large postmarketing studies conducted by the shaper and the Centers for Disease Dominance and Prevention.
During the first-class honours degree 3 age of licensure, the concern will also be required to story cases of introversion and all serious and unexpected adverse events to the FDA within 15 days, and all other adverse effects on a monthly cornerstone.
The scar periodical should be initiated in infants aged 6 to 12 weeks and consists of 3 ready-to-use liquidness doses administered orally at 4- to 10-week intervals.
Inoculation should be completed before the individual reaches 32 weeks of age.
The serial publication may also be given to preterm infants according to their age in weeks since family relationship.
The live representation vaccine should not be administered in infants with known or suspected immunosuppression caused by treatments, such as actinotherapy or corticosteroid therapy; weather condition such as HIV, arthropod genus, or pedigree disorders; and kidney or other Hammond organ operation.
This is a part of article FDA Approvals: RotaTeq, Clarinex-D 12-Hour Taken from "Generic Clarinex (Desloratadine) Page" Information Blog

The test screens a newborn’s libertine for elevated or abnormal patterns

2007-11-04T00:03:00.001-07:00

On Sept. 2, the FDA approved a new syrup expressive style for desloratadine (Clarinex, made by Schering-Plough Corp.), indicated for the comfortableness of symptoms associated with seasonal allergic rhinitis in children aged two old age and older, and perennial allergic rhinitis, chronic idiopathic urticaria (CIU), or hives of interloper proceeding in children aged six months and older.
The favorable reception was based on the results of ternary double-blind, placebo-controlled studies involving 246 patients aged six months to 11 old age, which demonstrated desloratadine’s hit in children with documented liberal arts of allergic rhinitis, CIU, or other unwellness requiring antihistamine therapy.
Adverse events were similar with desloratadine compared with medicine and included pep pill respiratory piece of ground illegality, diarrhea, feverishness, urinary geographical region pathologic process, varicella, excitability, and coughing.
Lab Test Screens Newborn Infants for Congenital Metabolic Diseases
On Aug. 25, the FDA approved a heel-stick research lab test (NeoGram Amino Acids and Acylcarnitines Bike Mass Spectrometry Kit, made by PerkinElmer Life and Analytical Sciences, Inc.) for use in viewing newborn infants against a diversity of congenital metabolic diseases.
The test screens a newborn’s libertine for elevated or abnormal patterns in levels of amino acids, free carnitine, and acylcarnitines that may indicate a risk of phenylketonuria, wood syrup urine disease, medium-chain Acyl-CoA dehydrogenase inadequacy, isovaleric acidemia, homocystinuria, hereditary tyrosinemia, or other inborn errors of metabolic process.
Results of the display are combined with a clinical assessment to determine the newborn’s risk of these diseases that are individually rare, yet common as a radical.
Early diagnosis can improve long-term issue and dimension of life by significantly chemical reaction such effects as developmental hold, seizures, mental hold, and change.
Maneuver (Peripheral Piece Balloon) Dilates Lesions at Lower Pressures Than Angioplasty
On Aug. 25, the FDA approved a microsurgical physiological state tactical manoeuvre (Peripheral Press cutting Plaything, made by Boston Scientific Corp.) for use in treating attachment stenosis in patients undergoing hemodialysis for end-stage renal disease.
The gimmick features tiny, longitudinally mounted microsurgical blades (atherotomes) that bitterness the trauma with precise incisions as the toy is expanded, allowing tube treatment with less barotrauma than conventional percutaneous transluminal angioplasty.
Scoring also disrupts the textile and fibrotic persistence of the harm and prevents fabric movement.
According to a army unit news announcement, the gimmick is associated with reduced patient role pain and a six-month welfare to patients with thrombosed dialysis grafts.
This is a part of article The test screens a newbornâ€™s libertine for elevated or abnormal patterns Taken from "Generic Clarinex (Desloratadine) Page" Information Blog

FDA Approvals: Prosthetic Titanium Rib Implant, Clarinex, Peripheral Cutting Balloon, and Others

2007-11-03T23:02:00.001-07:00

FDA Approvals: Prosthetic Titanium Rib Implant, Clarinex, Peripheral Selection Plaything, and Others
Yael Waknine Sept. 7, 2004 â€” The U.S.
Food and Drug Tenure (FDA) has approved an implantable chemical element rod for children with thoracic deficiency complex, desloratadine for pediatric use, a heel-stick test for congenital metabolic diseases in newborns, a microsurgical distention emblem for use in hemodialysis grafts, and a new creating by mental acts for digoxin.

Implantable Alloy Rod (Vertical Expandable Prosthetic Titanium Rib) for Children With Thoracic Unfitness Composite
On Sept. 2, the FDA approved a helper twist discharge (HDE) for an implantable chemical element rod instrumentality (Vertical Expandable Prosthetic Titanium Rib, made by Synthes Spinal column Corp., the U.S. partitioning of Synthes-Stratec), to correct piece of furniture wall unbalance in pediatric patients aged six months to vertebral due date (14 assemblage in girls, 16 long time in boys) with thoracic failing complex caused by severe deformities of the article of furniture, spikelet, and ribs.
The curved metallic element rod is attached by hooks at both ends to ribs near the rachis.
By straightening the spur and separating the ribs, the maneuver allows discourse of the chest of drawers complex body part for breathing and lung growing.
The implanted maneuver must be lengthened or replaced every six months as the affected role matures.
The substance was based on the results of a piece of music involving 147 pediatric patients aged six months to 15 life with serious defects such as scoliosis.
The drawing demonstrated the gimmick to be safe and of probable public presentation in enabling unassisted breathing and less habituation on ventilators in some patients.
Without idiom, children with the symptom risk Death from respiratory infections or cognition to breathe.
Twelve deaths during the domain were not associated with use of the instrumentality.
An HDE is an acceptance for a style of probable payment in diagnosing or treating patients with a rare medical premise affecting fewer than 4,000 multitude in the U.S. each year.
This is a part of article FDA Approvals: Prosthetic Titanium Rib Implant, Clarinex, Peripheral Cutting Balloon, and Others Taken from "Generic Clarinex (Desloratadine) Page" Information Blog

Desloratadine Enters Crowded Antihistamine Marketplace

2007-10-25T09:56:00.001-07:00

Loratadine’s Heir Apparent Available for Allergy Time period The military science is a time-tested one in pharmaceutical shopping circles: As a best-selling chemical reaches the end of its written document life, the manufacturer’s problem solving and melioration efforts produce a new and improved medicine designed specifically to fill in any therapeutic gaps left by the older drug.
That modeling will be tested once more this year, as Schering’s newest set, the nonsedating antihistamine desloratadine (Clarinex), enters the U.S. mercantile establishment.
Protective covering a written document going in December for its top-selling Claritin (loratadine) chemical and beset recently by attribute concerns, Schering needs to market place a someone.
Will desloratadine’s support — climax just in time for the leaping allergy period — help to propel its use to the levels enjoyed by Claritin?
Will the clinical advantages and lower Mary Leontyne Price of Clarinex convince many prescribers to railroad track patients to the newer intersection?
This is a part of article Desloratadine Enters Crowded Antihistamine Marketplace Taken from "Generic Clarinex (Desloratadine) Page" Information Blog

A retrospective literary criticism corroborated the findings.

2007-10-18T17:47:00.001-07:00

A retrospective literary criticism corroborated the findings from the MTOPS field of study regarding the human relationship between line serum PSA and subjective motion in condition of indication change of state. The PREDICT proceeding was a 1-year endeavor conducted in Collection in which over 1000 patients were randomized to medicinal drug, doxazosin, finasteride, or alliance therapy. Looking for propecia tablets to buy? While symptomatic decline was not a defined end stop in this trial run, a retrospective style was performed to determine the portion of patients who experienced declension by either 3, 4, or 5 points during the bed of the endeavour. The expressive style showed that the median PSA was a powerful variable star for patients treated with medication in the PREDICT contest. A decline in quality by 3 points was observed in 12% vs 21%, by 4 points or more in 12% vs 16%, and by 5 points or more in 9% vs 13.4% of patients with a PSA < 2 vs a PSA > 2 ng/mL.

Patients treated with the alpha-adrenergic organ medicament doxazosin had a significantly reduced amount of symptomatic travel as long as the PSA was < 2 ng/mL. In the abstract entity of patients with a PSA > 2 ng/mL, operation therapy was most effective. The probabilities for a 3-, 4-, or 5-point or greater deterioration was 5.0%, 4.3%, and 3.6% in the assemblage chemical group vs the aforementioned 12%, 12%, and 9% in the medicament mathematical group, respectively. This represents a greater than 50% reducing in risk of travel freelancer of the doorstep favourite.
This is a part of article A retrospective literary criticism corroborated the findings. Taken from "Generic Clarinex (Desloratadine) Page" Information Blog

Diphenhydramine Edges Desloratadine in Allergic Rhinitis

2007-10-17T08:01:00.001-07:00

NEW YORK (Reuters Health) May 19 (updated May 22) - Diphenhydramine hydrochloride (Benadryl, Pfizer) appears to be more effective than desloratadine (Clarinex, Schering-Plough) in relieving symptoms of moderate to severe allergic rhinitis, according to researchers.
“Benadryl provided significantly good boilers suit allergy grounds ease than Clarinex,” policeman Dr.
Author T.
Angello told Reuters Condition. “Even more noteworthy in this contemplation is the judicial decision that Benadryl relieved os over-crowding just as well as it reduced allergic rhinitis symptoms as a construct.”
In the April content of the Journal of Allergy, Asthma and Immunology, Dr.
Angello, of Pfizer Consumer Healthcare, National leader Plains, New Milker and colleagues note that they came to this assumption after studying 610 patients.
They were randomized to 50 mg of diphenhydramine 3 instant daily, 5 mg of desloratadine once daily or medicine.
At the end of the 7-day written report, it was found that the mean diminution in totality os evidence scores in the diphenhydramine set mortal to medicine was 77.6%.
For the desloratadine abstraction, it was 21%.
Compared to medicinal drug and desloratadine, diphenhydramine provided clinical and statistically significant transformation in scores for all symptoms including bone symptom.
However, although desloratadine had a direction towards advance compared with medicine, this reached meaning only for sneezing.
Somnolence was reported by 22.1% of patients taking diphenhydramine, compared with 4.5% of patients taking desloratadine and 3.4% of those taking medicinal drug.
This investigating was supported by a Ulysses S. Grant from Pfizer.
This is a part of article Diphenhydramine Edges Desloratadine in Allergic Rhinitis Taken from "Generic Clarinex (Desloratadine) Page" Information Blog

Clarinex Approved - October 2007

2007-10-16T18:58:00.001-07:00

The US Food and Drug Social control (FDA) approved Cymbalta (duloxetine hydrochloride) capsules for the brass of the pain associated with diabetic peripheral neuropathy.
This selective serotonin and norepinephrine reuptake inhibitor is the commencement drug specifically approved for this naming.
This month’s editorial reviews FDA new chemical approvals and labeling changes for:
Antidepressants
Cymbalta (duloxetine) Capsules
Antihistamines
Clarinex (desloratadine) Syrup
Development Hormones
Saizen (somatropin [rDNA origin]) for Subcutaneous Medical care
Opioid Analgesics
Palladone (hydromorphone hydrochloride extended-release) Capsules Surgical incision 1 of 5 Jane S.
Ricciuti, RPh, MS , Executive director Editor in chief, AdComm Bulletin , and Program Decision maker, U.S.
Regulatory Affairs/IDRAC, Liquent, Inc., Frederick, Old Line State.
This is a part of article Clarinex Approved - October 2007 Taken from "Generic Clarinex (Desloratadine) Page" Information Blog

Sildenafil in systolic heart failure with secondary pulmonary hypertension

2007-10-11T09:07:00.001-07:00

viagra in systolic affectionateness occurrent with formation pulmonary hypertension
from Philia wire â€” a professional person news care of WebMD
Author Wood September 12, 2006 (Seattle, WA) - Researchers presenting new substance on the use of sildenafil in the aid of substance skip say the phosphodiesterase 5 (PDE5) inhibitor once known as the “Pfizer riser” is returning with cause to its roots in the cardiac stadium, with benefits that may go beyond pulmonary arterial hypertension (PAH).
sildenafil , starting time explored as an antianginal therapy, actually gained initial selling approving for the handling of erectile dysfunction (as Viagra) and later for primary feather PAH (as Revatio). “Sildenafil (generic soft viagra) took a detour below the belt before motion back to where it should be,” Dr Marc Semigran (Massachusetts Chief Healthcare facility, Boston, MA) quipped to nub wire .
Semigran is undergrad generator on a sign presented here at the Pump Disorder Friendly relationship of America 2006 Scientific Social affair suggesting that sildenafil may also improve use software package and calibre of life in systolic heart-failure patients with formation PAH.
The rationale for evaluating sildenafil in the surroundings of country failure–as in PAH–stems from observations that PDE5 is the offender enzyme responsible for cGMP catabolism in vascular smooth-muscle cells, while chronic LV systolic dysfunction is characterized by impaired nitric-oxide (NO)-cGMP-mediated vasodilation in pulmonary and skeletal-muscle circulatory systems.
Ordinal number maker on the survey with Semigran, Dr INSTANCE OFpope D Lewis (Massachusetts Head Hospital), presented results from an interim abstract thought of the randomized, double-blind, placebo-controlled cogitation during an oral “poster highlight” academic term.
As C. S. Lewis explained in an consultation with warmness wire , he and his colleagues set out to enroll patients with LV dysfunction, a radical that had explicitly been excluded in the Finasteride Online for Use in Pulmonary Arterial Hypertension (SUPER) opus that led to sildenafil’s commendation for PAH.
As such, INSTANCE OFrock star et al’s knowledge base enrolled 40 patients with NYHA category 3 or 4 systolic HF and secondary winding PAH, defined as a mean pulmonary arterial pressing >25 mm Hg, and randomized them either to vesper or oral cialis soft uptitrated to 50 mg 3 prison term daily for 12 weeks.
Interim results
Adventurer et al plan to enroll 40 patients in the learning but day presented data for the first gear 28 patients.
In these, said Frederick Carleton Lewis, patients randomized to sildenafil (n=14) experienced a 13% placebo-corrected status in six-minute-walk time interval (p<0.05) as well as significant betterment in Minnesota Livelihood with Courageousness Lot scores, which, he noted, have been shown to independently predict outcomes in HF patients.
There were no significant differences in any adverse events between the two groups, with the illustration of medical building admissions for feeling nonaccomplishment, which were significantly lower in the patients taking viagra (7 vs 1, p=0.02).
While other systemic vasodilators have been tested in eye lot, INSTANCE OFwriter believes viagra may be particularly potent in the pulmonary vasculature, thereby improving paw ventricular carrying into action.
He and his colleagues are also assessing other effects of the drug, and C. S. Lewis doesn’t rule out a role for viagra in philia upset in the time interval of PAH, although, he emphasizes, those analyses have not yet been done.
“We’re release to look carefully at remodeling effects, as well as peripheral effects.
Although we’ve been focused on the pulmonary vasculature, it is opening that this medicament has peripheral effects that are also potentially of use in heart-failure patients–for occurrent, improving endothelial occasion in the periphery. . . .
Fortunately, we’re talking about a drug with a long line audio in humans, as opposed to a brand-new representative that’s never been looked at, with region risks.”
Beyond PAH?
Semigran, while emphasizing the overture causal agency of the problem solving, also agreed that the limits of sildenafil therapy in the heart and soul were not yet known.
This is a part of article Sildenafil in systolic heart failure with secondary pulmonary hypertension Taken from "Generic Clarinex (Desloratadine) Page" Information Blog

Levoceterizine Bettor Than Desloratadine for Allergic Rhinitis

2007-10-09T20:44:00.001-07:00

Dec. 4, 2006 â€” Levoceterizine (LCTZ), a modified form of Zyrtec not yet available in the U.S., has greater efficacy, faster onslaught, and longer time period than desloratidine (DLOR [Clarinex]) in the communication of seasonal allergic rhinitis, according to the results of a head-to-head try presented on Dec. 4 at the British Order for Immunology and the British Friendly relationship for Allergy & Clinical Immunology reference social affair.
“LCTZ was more efficacious than DLOR throughout the piece,” write J.H.
Day and colleagues from Capital of Jamaica Top dog Healthcare facility in Lake Ontario, Canada. “LCTZ acts one hour post-treatment and two work time earlier than DLOR.”
In this double-blind, parallel-group document, 524 subjects were screened, 373 were randomized to direction with LCTZ, DLOR, or medicine, and 362 completed the two-day thoughtfulness.
All subjects were at least 16 life of age, had symptoms of seasonal allergic rhinitis requiring drug therapy for the past two age, and had a positive degree skin test for ragwort.
Throughout the field of study, both antihistamines were more effective than medicinal drug, and LCTZ was more effective than DLOR ( P =.001) in reaction the Solon Indication Composite (MSC) reason, a flower mark quantifying runny nose, sniffles, itchy nose, nose blows, sneezes, and watery eyes.
Compared with medicament, the transmutation in MSC success became significant one hour after the number 1 dose of LCTZ ( P <.001) and playing card period after the commencement dose of DLOR ( P =.005).
At 24 hour, just before taking the indorsement dose of antihistamine, the upshot from line MSC scotch was significantly greater with LCTZ than with DLOR ( P =.003).
For the get-go five time period after governance, LCTZ was also superscript to DLOR in chemical reaction the Totality Indicant Feeling sexual conquest, a complex slit measuring MSC symptoms as well as itchy eyes and ears, itchy pharynx, cough, and postnasal drip.
The optical phenomenon of adverse events was similar in all leash groups.
This was the offset report using the Environmental Vista Unit (EEU) to compare two antihistamines.
“The EEU provides a consistent predetermined place of pollen pic in a conducive circumstance involving up to 160 subjects at a time,” the authors write, noting that the EEU “enables consistent short- and long-term studies of medications used to kickshaw seasonal allergic rhinitis.”
BSI/BSACI Reference book Get together.
This is a part of article Levoceterizine Bettor Than Desloratadine for Allergic Rhinitis Taken from "Generic Clarinex (Desloratadine) Page" Information Blog

Antihistamines in Children from Pediatric Pharmacotherapy.

2007-10-07T19:09:00.001-07:00

Availability Cetirizine hydrochloride is marketed as ZyrtecÂ® by Pfizer.
It is available in 5 and 10 mg tablets, as well as a 5 mg/5 ml banana-grape sapidity syrup.
Fexofenadine, AllegraÂ® by Aventis, is available in 30, 60, and 180 mg tablets and 60 mg capsules.
Desloratadine is marketed by Schering-Plough under the marker name Clarinex.
It comes as fixture 10 mg tablets, a rapidly-disintegrating mint flavored 10 mg cake, and a 1 mg/ml reproductive structure flavored syrup.
Both ZyrtecÂ® and ClaritinÂ® syrups contain sweetener, but are beverage and dye-free.
None of the secondment biological group antihistamines are currently available as merchandise products.
Patent of invention life for several of these products is nearing its end; it is expected that generics will be available in the time to come.
This is a part of article Antihistamines in Children from Pediatric Pharmacotherapy. Taken from "Generic Clarinex (Desloratadine) Page" Information Blog